

PARVESH KUMAR, M.D.
Curriculum Vitae – Table of Contents

<i>Contents</i>	<i>Page Number</i>
Table of Contents	1
A -- Personal Information	2
B -- Education, Honors / Awards, Licensure & Certification	2-3
C -- Work Experience and Accomplishments	4-7
1. University of Nevada, Las Vegas – School of Medicine (SOM).....	4
2. University of Kansas – School of Medicine.....	5
3. University of Southern California – Keck School of Medicine.....	6
4. Rutgers – Robert Wood Johnson School of Medicine.....	6-7
5. St. Jude Children’s Research Hospt., & Univ. of Tenn. Sch. of Medicine.....	7
D -- Academic & Professional Appointments	8-20
1. Academic Appointments.....	8-11
2. Clinical Hospital Appointments.....	11-13
3. Specific Administrative Appointments / Committee Service – Universities, Schools of Medicine, Hospitals & Other Organizations.....	13-20
E -- Research Activities	21-30
1. Major Areas of Research Interest.....	21
2. Research Grants / Grant Funding.....	21-24
a. Current.....	21
b. Completed.....	21-24
3. Invited Reviewer of Grant Study Sections.....	24-25
4. Invited Ad Hoc Reviewer of Peer Review Journals.....	26
5. Clinical Trials – Principal Investigator (PI) / Co-PI.....	26-28
a. National Clinical Trials.....	26
b. Institutional Clinical Trials.....	27-28
6. National Research Groups – Appointed Leadership Positions and Invited Committee Memberships.....	28-30
F -- Society Memberships	30
G -- Teaching Activities	31-32
H -- Invited Speakerships	33-54
1. Panels.....	33-36
2. National and International Invited Lectures.....	36-46
3. Presentations at Major National and International Meetings (as Presenter and / or First Author).....	47-54
I -- Scholarly Publications	54-81
1. Book Chapters.....	54-55
2. Published / Presented Abstracts.....	55-75
3. Manuscript Publications.....	76-81

PARVESH KUMAR, M.D.

CURRICULUM VITAE

B. EDUCATION, HONORS / AWARDS, LICENSURE and CERTIFICATION:

Education

Undergraduate Education	Chemical Engineering, B.S. with Honors, University of Kansas, Lawrence, Kansas August 1977 – July 1981
Medical School	Doctorate of Medicine, University of Kansas School of Medicine, Kansas City, KS August 1981 – May 1986
Internship	Thomas Jefferson Univ. Hospital, Philadelphia, PA July 1986 – June 1987
Residency	Dept. of Radiation Oncology and Nuclear Medicine, Thomas Jefferson Univ. Hospt., Philadelphia, PA July 1987 – June 1990

Honors and Awards

Dean's Honor Roll (7/8 semesters)
University of Kansas, Lawrence, Kansas
August 1977 – June 1981

B. EDUCATION, HONORS / AWARDS, LICENSURE and CERTIFICATION (continued):

Honors and Awards (continued)

American Institute of Chemical Engineers Junior Achievement Award
for maintaining the highest scholastic standing (i.e., GPA=3.89/4.0) among all
Juniors at the University of Kansas School of Engineering, Department of
Chemical and Petroleum Engineering, Lawrence, KS
September 1980

Medical Student Research Scholarship Award
Department of Biochemistry, University of Kansas School of Medicine
Kansas City, Kansas
Summer 1983

American Cancer Society Clinical Oncology Fellowship
Department of Radiation Oncology, Thomas Jefferson University Hospital
Philadelphia, PA
July 1, 1989 - June 30, 1990

American Society of Therapeutic Radiation Oncology, and European Society of
Therapeutic Radiology and Oncology Travel Award

- 1995

Selected by Peers as one of “The Best Doctors in America”

- 2005 – 2006
- 2007 – 2008
- 2009 – 2010
- 2011 – 2012
- 2013
- 2014
- 2015 – 2016

State Medical Licensures

- Pennsylvania: 1989
- Tennessee: 1990
- New Jersey: 1998
- California: 2003
- Kansas: December 18, 2009
- Nevada: October 25, 2017

Board Certification

- American Board of Radiology
- 1990 (Radiation Oncology)

C. WORK EXPERIENCE & ACCOMPLISHMENTS

1. University of Nevada, Las Vegas - School of Medicine: February 2016 – Present

a) Major Administrative / Academic Positions & Roles

- i.* Tenured Professor
- ii.* Principal Investigator, Mountain West (MW) Clinical & Translational Research Infrastructure Network (CTR-IN) Program – a National Institute of Health (NIH) Funded U-54 Grant
- iii.* Vice Dean of Research
- iv.* Chair, Department of Radiation Oncology

b) Major Accomplishments

- i.* Renewed the NIH funded MW CTR-IN Grant (#2U54GM104944) involving 13 Universities across 7 states for \$20.3M for another 5 years in August 2018 -- this grant has been used to establish, develop and grow sustainable research infrastructure in the MW region such that during the first 6 years, an investment of 6.2M in 93 pilot grants has led to \$53.32M in extramural grant funding, representing a return on investment of 863%.
- ii.* Developed & established the UNLV SOM's Clinical Research Office
 - Total Extramural Grant Funding stood at approximately \$26.3M in 2019
 - Developed the capability to conduct Phase II – III Clinical Trials
 - Recruited biostatistician to conduct and support research projects
- iii.* Achieved LCME Preliminary Accreditation – July 2016
 - Served as a Member of the “Senior Leadership” Team and the Senior Member of the “Research/Medical Student Research Opportunities and Academic Environment” Team
- iv.* Achieved LCME Provisional Accreditation -- October 2019
 - Served as Member of the “Senior Leadership” Team and the “Departmental Chairs” Team for the February 2019 LCME site visit; also served as the Senior Member of the “Research/Medical Student Research and Academic Environment” Team
 - This LCME Report indicated that the “funding and infrastructure are sufficient to support faculty scholarly activity/research and are growing.”

2. University of Kansas - School of Medicine (SOM): February 2010 – February 2016

a) Major Administrative / Academic Positions & Roles

- i. Tenured Professor
- ii. Chair, Department of Radiation Oncology
- iii. President / CEO – Radiation Therapy Foundation, Inc.
- iv. Associate Director of Clinical Research, Univ. of Kansas Cancer Center, a National Cancer Institute (NCI) designated Cancer Center
- v. Principal Investigator, Radiation Therapy Oncology Group (RTOG) & NRG Oncology (both NCI Funded Co-operative Oncology Groups)
- vi. Site Leader, U.S. Oncology Group – University of Kansas Cancer Center
- vii. Clinical Chief of Service & Medical Director, Dept. of Radiation Oncology, Univ. of Kansas Hospital

b) Major Accomplishments

i. Clinical / Faculty Practice Plan

- Re-Built the Department of Radiation Oncology from one of the smallest to one of the largest in the USA as follows:
 - Total Faculty increased from 4 to 28 (700% increase)
 - Radiation Oncologists increased from 2 to 15
 - Number of Linear Accelerators increased from 3 to 11, and clinical facilities increased from 1 to 7
- Radiation Oncology Patient consultations tripled from 1,048 to 3,109
- Served as President / CEO of Radiation Therapy Foundation, Inc. -- Responsibilities included supervision and management of the departmental faculty practice plan encompassing billings, collections, faculty / staff recruitment and compensation, and revenue distribution
 - Departmental Faculty Practice Plan annual revenue increased by >600%, and Reserves increased from \$331K to >\$4.4M between 2010 and 2015

ii. Research

- Played integral role as Associate Director of Clinical Research for the KU Cancer Center to achieve National Cancer Institute (NCI) Cancer Center Designation in 2012 after more than a 3 decade effort
- Achieved Main Member Status from Affiliate Member status for Radiation Therapy Oncology Group (RTOG) and NRG Oncology Group, both NCI funded Co-operative Oncology Groups

iii. Education

- Radiation Oncology Residency 5 year average Board Exam Pass Rate Improved from 0% to 100%

iv. Fundraising

- Worked and interacted personally with philanthropic donors to further support and enhance the Department of Radiation Oncology / KU Cancer Center.

3. Univ. of Southern California (USC) - Keck Sch. of Medicine: May 2003 – Feb. 2010

a) Major Administrative / Academic Positions & Roles

- i.* Tenured Professor
- ii.* Chair, Department of Radiation Oncology
- iii.* President / CEO – USC Radiation Oncology Associates, Inc.
- iv.* Radiation Oncology Medical Director, Norris Cancer Center Hospital
- v.* Chief of Service, Dept. of Radiation Oncology, Los Angeles County (LAC) – USC Medical Center
- vi.* Principal Investigator, Radiation Therapy Oncology Group

b) Major Accomplishments

i. Clinical / Faculty Practice Plan

- Significantly increased the volume of radiation therapy patients at the Norris Cancer Center Hospital
- Planned and coordinated the design of the new Department of Radiation Oncology at LAC-USC Medical Center including purchase of 3 new Linear Accelerators and CT Simulator
- Doubled the number of Physics faculty from 4 to 8
- Recruited 5 Radiation Oncologists
- Served as President / CEO of the USC Radiation Oncology Associates, Inc. – Responsibilities included supervision and management of the departmental faculty practice plan encompassing billings, collections, faculty / staff recruitment and compensation, and revenue distribution
- Negotiated an almost tripling of the budget support for the Radiation Oncology Service from LAC-USC Medical Center

ii. Research

- Obtained 2 major competitive research grants in Prostate Cancer as Principal Investigator from the U.S. Department of Defense for \$1.3M
- Further developed the department's research infrastructure by increasing accruals to RTOG and Pharma funded clinical trials

iii. Education

- Founded and initiated the Los Angeles City-Wide Radiation Oncology Resident Mock Oral Board Examinations with UC Irvine, UCLA, Kaiser Permanente, and Vantage Oncology

4. Rutgers - Robert Wood Johnson (RWJ) Sch. of Medicine: Aug. 1998 – April 2003

a) Major Administrative / Academic Positions & Roles

- i.* Tenured Professor
- ii.* Chair, Department of Radiation Oncology
- iii.* Chief of Service, RWJ Univ. Hospital and St. Peter's Univ. Hospital
- iv.* Associate Cancer Center Director, Cancer Institute of New Jersey, a NCI Designated Cancer Center

C. WORK EXPERIENCE & ACCOMPLISHMENTS (continued)

4. Rutgers - RWJ Sch. of Medicine: Aug. 1998 – April 2003 (continued)

b) Major Accomplishments

i. Overall

- Founded and established a new academic Department of Radiation Oncology
- Established and developed the department's clinical, research and administrative infrastructures

ii. Clinical

- Expanded the program from 1 to 3 clinical facilities
- Planned and coordinated the design of the new Department of Radiation Oncology facilities at RWJ University Hospital in New Brunswick, NJ and in Hamilton, NJ, including purchase of 3 new Linear Accelerators and CT Simulators
- Recruited 8 new faculty members
- Significantly increased the department's patient volume and clinical research activities

iii. Research

- Developed and grew the Department's research infrastructure to conduct clinical trials
- Conducted as PI an Investigator Initiated Pharma Funded (Aventis Oncology) first ever Phase I Clinical Trial of concurrent docetaxel with radiation therapy in advanced prostate cancer

5. St. Jude's Children's Research Hospital (SJCRH), University of Tennessee – School of Medicine & Veterans Admin. Med. Ctr.: August 1990 – Aug. 1998

a) Major Administrative / Academic Positions & Roles

i. Tenured Associate Professor

ii. Chief of Service, Memphis Veterans Administration Medical Center

b) Major Accomplishments

i. Overall

- Established an academic clinical, research and teaching radiation oncology program at the Memphis Veterans Administration Medical Center including the planning and design of a new department and purchase of a new linear accelerator

ii. Clinical

- Instrumental in recruiting several radiation oncologists and physicists to the Department of Radiation Oncology

iii. Research

- Conducted several national NCI sponsored Clinical Trials as PI / Co-PI (CALGB Protocols #8935, #9134 on Lung Cancer, CALGB Protocol #9493 on Prostate Cancer, and RTOG Protocol #9615 on Locally Advanced Head and Neck Cancer)

D. ACADEMIC & PROFESSIONAL APPOINTMENTS

Academic Appointments

Professor with Tenure

University of Nevada Las Vegas School of Medicine,
Las Vegas, NV
February 2016 – Present

Principal Investigator, Mountain West (MW) Clinical and Translational Research Infrastructure Network (CTR-IN), a National Institute of Health Funded U-54 Grant

University of Nevada Las Vegas School of Medicine,
Las Vegas, NV
April 2016 - Present

Vice Dean of Research

University of Nevada Las Vegas School of Medicine,
Las Vegas, NV
November 2017 – May 2020

Senior Associate Dean of Clinical Research

University of Nevada Las Vegas School of Medicine,
Las Vegas, NV
February 2016 – October 2017

Chair, Department of Radiation Oncology

University of Nevada Las Vegas School of Medicine,
Las Vegas, NV
February 2016 – May 2020

Contact Principal Investigator, NRG Oncology

University of Kansas Cancer Center, a NCI designated Cancer Center
University of Kansas School of Medicine, Kansas City, KS
March 2014 – February 2016

Site Research Leader, US Oncology

University of Kansas Cancer Center, a NCI designated Cancer Center
University of Kansas School of Medicine, Kansas City, KS
July 2012 – February 2016

Principal Investigator, Radiation Therapy Oncology Group

University of Kansas Cancer Center, a NCI designated Cancer Center
University of Kansas School of Medicine, Kansas City, KS
April 2012 – February 2016

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Academic Appointments (continued):

Associate Director of Clinical Research

University of Kansas Cancer Center, a NCI designated Cancer Center
University of Kansas School of Medicine, Kansas City, KS
October 2010 – February 2016

Interim Deputy Cancer Center Director

University of Kansas Cancer Center, a NCI designated Cancer Center
University of Kansas School of Medicine, Kansas City, KS
February 2010 – August 2010

Professor with Tenure

University of Kansas School of Medicine, Kansas City, KS
February 2010 – February 2016

President and Chief Executive Officer

Radiation Therapy Foundation, a Kansas Nonprofit 501(c)(3) Corporation
Department of Radiation Oncology
University of Kansas School of Medicine, Kansas City, KS
February 2010 – July 2015

Chair (Joe and Jean Brandmeyer Chair), Department of Radiation Oncology

University of Kansas School of Medicine, Kansas City, KS
February 2010 – July 2015

Professor with Tenure

University of Southern California Keck School of Medicine
Los Angeles, California
Tenure (May 2004 – February 12, 2010)
May 2003 – February 2010

President and Chief Executive Officer

USC Radiation Oncology Associates Inc., a CA Nonprofit 501(c)(3) Corp.
Department of Radiation Oncology
University of Southern California Keck School of Medicine
May 2003 – February 2010

Chairman, Department of Radiation Oncology

University of Southern California (USC) Keck School of Medicine
Los Angeles, California
May 2003 – February 2010

Professor with Tenure, Robert Wood Johnson Medical School (RWJMS) /

University of Medicine and Dentistry of New Jersey (UMDNJ)
New Brunswick, New Jersey
July 2002 – April 2003

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Academic Appointments (continued):

Chairman, Department of Radiation Oncology
Robert Wood Johnson Medical School / University of Medicine and
Dentistry of New Jersey
New Brunswick, New Jersey
August 1998 – April 2003

Associate Cancer Center Director for Radiation Oncology
Cancer Institute of New Jersey at RWJMS / UMDNJ
New Brunswick, New Jersey
August 1998 – April 2003

Tenured Associate Professor
Robert Wood Johnson Medical School / University of Medicine and
Dentistry of New Jersey
New Brunswick, New Jersey
August 1998 – June 2002

Tenured Associate Professor, Department of Radiation Oncology
University of Tennessee, Memphis
Memphis, Tennessee
July 1996 – August 1998

Associate Professor, Department of Radiation Oncology
University of Tennessee, Memphis
Memphis, Tennessee
July 1995 – August 1998

Assistant Professor, Department of Radiology, Section of Radiation Oncology
University of Tennessee, Memphis
Memphis, Tennessee
August 1990 – June 1995

*Clinical Fellow, American Cancer Society, Department of Radiation Oncology
and Nuclear Medicine*
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
July 1989 – June 1990

Chief Resident, Department of Radiation Oncology and Nuclear Medicine
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
July 1989 – June 1990

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Academic Appointments (continued):

Resident, Department of Radiation Oncology and Nuclear Medicine Thomas
Jefferson University Hospital
Philadelphia, Pennsylvania
July 1987 – June 1989

Intern, Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
July 1986 – June 1987

Clinical Hospital Appointments

Staff Radiation Oncologist
University of Kansas Hospital
Kansas City, Kansas
February 2010 – February 2016

Clinical Chief of Service and Medical Director, Dept. of Radiation Oncology
University of Kansas Hospital
Kansas City, Kansas
February 2010 – July 2015

Staff Radiation Oncologist
Children's Hospital Los Angeles
Los Angeles, California
November 2004 – February 2010

Chief of Service, Department of Radiation Oncology
Los Angeles County (LAC) – University of Southern California Medical
Center
Los Angeles, California
July 2004 – February 2010

Staff Radiation Oncologist
Los Angeles County (LAC) – University of Southern California Medical
Center
Los Angeles, California
September 2003 – February 2010

Staff Radiation Oncologist
University of Southern California (USC) Keck School of Medicine
(KSOM) / Norris Comprehensive Cancer Center and Hospital
Los Angeles, California
July 2003 – February 2010

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Clinical Hospital Appointments (continued):

Staff Radiation Oncologist

University of Southern California KSOM / University Hospital
Los Angeles, California
July 2003 – February 2010

Director, Division of Radiation Oncology

Norris Cancer Center Hospital at Keck School of Medicine of University
of Southern California
Los Angeles, California
May 2003 – February 2010

Chief of Service, Radiation Oncology Service

Robert Wood Johnson University Hospital
New Brunswick, New Jersey
2001 – April 2003

Chairman, Department of Radiation Oncology

St. Peter's University Hospital
New Brunswick, New Jersey
August 1998 – April 2003

Staff Radiation Oncologist

Robert Wood Johnson University Hospital
New Brunswick, New Jersey
November 1998 – April 2003

Chief of Service, Radiation Oncology Service

Veterans Administration Medical Center
Memphis, Tennessee
June 1995 – August 1998

Staff Radiation Oncologist / Clinical Division Head

Radiation Oncology Service, Veterans Administration Medical Center
Memphis, Tennessee
August 1990 – May 1995

Consultant, Department of Radiation Oncology

St. Jude Children's Research Hospital
Memphis, Tennessee
August 1990 – June 1996

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Clinical Hospital Appointments (continued):

Staff Radiation Oncologist

The University of Tennessee Bowld Hospital
Memphis, Tennessee
August 1990 – August 1998

Staff Radiation Oncologist

The Regional Medical Center
Memphis, Tennessee
July 1990 – August 1998

Specific Administrative Appointments / Committee Service: Universities, Schools of Medicine, Hospital(s) or Other Organizations:

Member, Program Committee

International Symposium on Mathematical and Computational Oncology
Incline Village, Lake Tahoe, NV
September 2018 – October 2019

Member, American Association of Medical Colleges (AAMC) – Group on Research Advancement and Development (GRAND)

March 2018 – Present

Member, Internal Advisory Committee

Center of Biomedical Research Excellence (COBRE) -- Center for Neurodegeneration & Translational Neuroscience, a NIH Funded Program
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV
July 2016 – Present

Senior Member -- “Research/Medical Student Research Opportunities and Academic Environment” Team, & Member -- “Senior Leadership” Team Liaison Committee on Medical Education (LCME) Preliminary Site Visit

University of Nevada Las Vegas School of Medicine
Las Vegas, NV
July 18 – 19, 2016

Member, Faculty Appointments, Tenure and Promotion Committee

University of Nevada Las Vegas School of Medicine
Las Vegas, NV
June 2016 – March 2018

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Specific Administrative Appointments / Committee Service: Universities, Schools of Medicine, Hospital(s) or Other Organizations (continued):

Chair, Search Committee for the Chair of the Department of Internal Medicine
University of Nevada Las Vegas School of Medicine
Las Vegas, NV
June 2016 – June 2017 (Chair)
July 2017 – May 2018 (Member)

Member, Search Committee for the Vice President of Research at the
University of Nevada Las Vegas
Las Vegas, NV
October 2016 – April 2017

Member, Hospital and Research Institute Research Committee
University of Kansas Physicians, Inc.
Kansas City, KS
2014 – February 2016

Member, Search Committee Member for the Position of the Executive Director
for the University of Kansas Medical Center Research Institute, Inc.
Fairway, KS
June 2014 – November 2014

Member, Leadership Team, Frontiers: The Heartland Institute for Clinical and
Translational Research (CTSA)
University of Kansas Medical Center
Fairway, KS
April 2013 – February 2016

Elected Member (By University of Kansas School of Medicine Chairs Council)
Board of Directors
University of Kansas Physicians, Inc.
Kansas City, KS
January 2012 – July 2015

Member, Search Committee Member for the Position of the Executive Vice
Chancellor for the University of Kansas Medical Center
Kansas City, KS
December 2011 – November 2012

Member, Cancer Center Patient Care Standards Committee
The University of Kansas Cancer Center
Kansas City, KS
November 2011 – February 2016

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Specific Administrative Appointments / Committee Service: Universities, Schools of Medicine, Hospital(s) or Other Organizations (continued):

Chair, Clinical Research Leadership Committee
The University of Kansas Cancer Center
Kansas City, KS
August 2011 – February 2016

Chair, Cancer Center Clinical Operations Committee, Radiation Oncology
The University of Kansas Cancer Center
Kansas City, KS
June 2011 – July 23, 2015

Member, Cancer Committee
The University of Kansas Cancer Center
Kansas City, KS
April 2010 – February 2016

Member, Oncology Service Line Committee
The University of Kansas Cancer Center
Kansas City, KS
March 2010 – July 2015

Member, The University of Kansas Cancer Center (an NCI-designated Cancer Center)
The University of Kansas Cancer Center
Kansas City, KS
February 2010 – February 2016

Member, Cancer Center Director's Committee
The University of Kansas Cancer Center
Kansas City, KS
February 2010 – February 2016

Member, Cancer Center Associate Director's Committee
The University of Kansas Cancer Center
Kansas City, KS
February 2010 – February 2016

Member, Cancer Center Drug Discovery, Delivery & Experimental Therapeutics Program (a CCSG P-30 Scientific Program)
The University of Kansas Cancer Center
Kansas City, KS
February 2010 – February 2016

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Specific Administrative Appointments / Committee Service: Universities, Schools of Medicine, Hospital(s) or Other Organizations (continued):

Member, Executive Committee

University of Kansas School of Medicine
Kansas City, KS
February 2010 – July 2015

Member, Cancer Center Leadership Council

The University of Kansas Cancer Center
Kansas City, KS
February 2010 – February 2016

Member, Executive Committee of the Medical Staff

University of Kansas Hospital
Kansas City, Kansas
February 2010 – July 2015

Member, Dean's Research Cabinet

University of Southern California Keck School of Medicine (KSOM)
Los Angeles, California
August 2009 – February 2010

Member, Investment Subcommittee

University of Southern California Care Medical Group, Inc.
University of Southern California Keck School of Medicine
Los Angeles, California
April 2008 – February 2010

Interviewer, Office of Medical Student Admissions

University of Southern California Keck School of Medicine
Los Angeles, California
July 2004 – February 2010

Member, Cancer Committee

Los Angeles County (LAC) / University of Southern California Medical
Center
Los Angeles, California
October 2004 – February 2010

Member, Cancer Investigation Committee

University of Southern California KSOM / Kenneth Norris Jr. Cancer
Hospital
Los Angeles, California
September 2003 – February 2010

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Specific Administrative Appointments / Committee Service: Universities, Schools of Medicine, Hospital(s) or Other Organizations (continued):

Member, Medical Executive Committee

University of Southern California KSOM / Kenneth Norris Jr. Cancer
Hospital
Los Angeles, California
September 2003 – February 2010

Member, Cancer Committee

University of Southern California KSOM / Kenneth Norris Jr. Cancer
Hospital
Los Angeles, California
August 2003 – February 2010

Member, Faculty Appointment and Promotions Committee

University of Southern California Keck School of Medicine
Los Angeles, California
August 2003 – February 2010

Member, Medical Executive Committee

Los Angeles County (LAC) / Univ. of Southern California Med. Center
Los Angeles, California
July 2003 – February 2010

Member, Finance Committee

University of Southern California Care Medical Group, Inc.
Los Angeles, California
June 2003 – February 2010

Member

Norris Comprehensive Cancer Center (a NCI-designated Cancer Center)
University of Southern California KSOM
Los Angeles, California
June 2003 – February 2010

Member, Executive Council

Keck School of Medicine, University of Southern California KSOM
Los Angeles, California
May 2003 – February 2010

Member, Credentials Committee and Medical Board

Robert Wood Johnson University Hospital
New Brunswick, New Jersey
2001 – April 2003

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Specific Administrative Appointments / Committee Service: Universities, Schools of Medicine, Hospital(s) or Other Organizations (continued):

Member, Gala Leadership Committee
Award of Hope Annual Gala and Benefit Auction
The Cancer Institute of New Jersey
New Brunswick, New Jersey
July 2002 – November 2002

Member, Review Committee for Planning and Administration
University of Medicine and Dentistry of New Jersey / Robert Wood
Johnson Medical School
New Brunswick, New Jersey
2001 – 2002

Member, Search Committee Member for the Chief of Radiation Oncology
University of Medicine and Dentistry of New Jersey / Robert Wood
Johnson Medical School Campus at Camden, New Jersey
New Brunswick, New Jersey
2001 – 2002

Member, Gala Leadership Committee
Award of Hope Annual Gala and Benefit Auction
The Cancer Institute of New Jersey
New Brunswick, New Jersey
July 2001 – November 2001

Member, Cardiovascular Services Working Group
Robert Wood Johnson University Hospital
New Brunswick, New Jersey
March 2001 – April 2003

Member, Cancer Working Group
Robert Wood Johnson University Hospital
New Brunswick, New Jersey
March 2001 – April 2003

Member, Cancer Committee
Robert Wood Johnson University Hospital
New Brunswick, New Jersey
January 2001 – April 2003

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Specific Administrative Appointments / Committee Service: Universities, Schools of Medicine, Hospital(s) or Other Organizations (continued):

Member, Cancer Committee

Saint Peter's University Hospital
New Brunswick, New Jersey
January 2000 – April 2003

Member, Institutional Review Board (IRB) Committee

Robert Wood Johnson University Hospital / Robert Wood Johnson
Medical School / UMDNJ
New Brunswick, New Jersey
2000 – April 2003

Member, Internal Advisory Board for the Dean and Betty Gallo

Prostate Cancer Institute
Cancer Institute of New Jersey
New Brunswick, New Jersey
1999 – April 2003

Member, Search Committee for the Chief of Gynecology-Oncology

Robert Wood Johnson Med. Sch. / UMDNJ / Cancer Institute of NJ
New Brunswick, New Jersey
1999 – 2000

Member, Executive Council Committee, Cancer Institute of New Jersey

New Brunswick, New Jersey
August 1998 – April 2003

Member, Scientific Advisory Committee, Cancer Institute of New Jersey

New Brunswick, New Jersey
August 1998 – April 2003

Director, Genito-Urinary Tumor Study Group, Cancer Institute of New Jersey

New Brunswick, New Jersey
August 1998 – April 2003

Member, Performance Improvement Committee

St. Peter's University Hospital
New Brunswick, New Jersey
August 1998 – April 2003

Member, Continuing Medical Education Committee

Robert Wood Johnson Medical School / UMDNJ
New Brunswick, New Jersey
August 1998 – April 2003

D. ACADEMIC & PROFESSIONAL APPOINTMENTS (continued)

Specific Administrative Appointments / Committee Service: Universities, Schools of Medicine, Hospital(s) or Other Organizations (continued):

Member, Executive Council Committee

Robert Wood Johnson Medical School / UMDNJ
New Brunswick, New Jersey
August 1998 – April 2003

Member, The Cancer Institute of New Jersey (an NCI-designated Cancer Ctr.)

New Brunswick, New Jersey
August 1998 – April 2003

Member, Chief of Staff Search Committee

Veterans Administration Medical Center
Memphis, Tennessee
August 1997 – August 1998

Member, Dean's Search Committee for the Chairman of the Department of

Radiation Oncology
University of Tennessee, Memphis
Memphis, Tennessee
February 1996 – July 1996

Member, Institutional Review Board (IRB) Committee

Veterans Administration Medical Center
Memphis, Tennessee
1996 – 1998

Co-Director, Genito-Urinary Oncology Program

University of Tennessee, Memphis
Memphis, Tennessee
1995 – 1998

Member, Clinical Privileges Committee

St. Jude Children's Research Hospital
Memphis, Tennessee
1994 – 1997

Member, Cancer Committee

Veteran's Administration Medical Center
Memphis, Tennessee
1990 – 1998

E. RESEARCH ACTIVITIES

Major Areas of Research Interest

1. Head and Neck Cancer – Novel strategy of using high dose intra-arterial chemotherapy and concurrent radiation therapy; the use of comprehensive hyperfractionated re-irradiation for recurrent disease.
2. Prostate Cancer – Testing and evaluating the novel strategy of radiosensitization with taxanes for high risk prostate cancer; and, evaluating the safety and feasibility of adjuvant taxane radiosensitization for high-risk prostate cancer.
3. Lung Cancer – Testing multi-modality therapy in locally advanced disease; and, evaluating new radiotherapy techniques in the treatment of lung cancer.

Research Grants / Grant Funding:

Current:

1. Mountain West (MW) Clinical and Translational Research Infrastructure Network (CTR-IN) Grant - #2U54GM104944
Role – Principal Investigator (August 8, 2018 - Present)
Total Funding: \$20,285,747
Funding Period: August 8, 2013 – June 30, 2023
Funding Agency: National Institute of Health (NIH) / National Institute of General Medical Sciences (NIGMS)

Completed

2. Mountain West (MW) Clinical and Translational Research Infrastructure Network (CTR-IN) Grant - #1U54GM104944
Role – Principal Investigator (April 1, 2016 – August 7, 2018)
Total Funding: \$19,915,508
Funding Period: September 15, 2013 – August 7, 2018
3. Univ. of Kansas Cancer Center Large Investigator Initiated Trial: “Phase II Randomized Clinical Trial of 3-D Conformal RT vs IMRT in Post-Prostatectomy Prostate Cancer Patients”
Role – Principal Investigator (until February 2016)
Total Funding: \$81,670
Period: July 2015 – June 2017 (estimated for completion)
Funding Sponsor: University of Kansas Cancer Center
4. National Institute of Health Cancer Center Support Grant 5 P30 CA168524-03 (PI: Roy Jensen, MD)
Role – Co-Investigator (Associate Director of Clinical Research: October 2010 - February 2016)
The University of Kansas Cancer Center
Total Annual Funding: \$981,805 (Source: NCI)
Funding Period: July 11, 2013 – June 30, 2017
Funding Sponsor: NIH / National Cancer Institute

E. RESEARCH ACTIVITIES (continued)

Research Grants / Grant Funding (continued):

Completed (continued):

5. NRG Oncology / National Cancer Institute U10 CA021661
Role: Institutional Contact Principal Investigator (April 2012 – February 2016)
The University of Kansas Cancer Center
Total Funding: \$257,436 (estimated, patient accrual dependent)
Funding Period: June 26, 2008 – February 2016
Funding Sponsor: NRG Oncology / National Cancer Institute (NCI)

6. “M10-897: A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects with Brain Metastases from Non-Small Cell Lung Cancer”
Role: Institutional Principal Investigator (AbbVie Pharmaceuticals Sponsored Multi-Institutional Trial)
University of Kansas School of Medicine
Total Funding: \$599,289.17 (estimated, patient accrual dependent)
Funding Sponsor: AbbVie Pharmaceuticals
Funding Period: August 2013 – July 2014

7. “Clinical Trial Award – A Phase I/II Trial of Adjuvant 3-D Conformal Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0M0 Prostate Cancer” [PC061648]
Role: Principal Investigator -- Investigator Initiated Clinical Trial
Univ. of Southern California Keck SOM and Univ. of KS SOM
Total Funding: \$1,220,345
Funding Period: September 1, 2007 – September 30, 2011
Funding Sponsor: Department of Defense (US Army Medical Research and Material Command, Congressionally Directed Medical Research Programs)

8. “Docetaxel plus 6-Month Androgen Suppression and Radiation Therapy vs. 6-Month Androgen Suppression and Radiation Therapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial”
Role: Institutional PI
University of Southern California Keck School of Medicine
Total Funding: \$96,097.13 (estimated, patient accrual dependent)
Funding Period: 2007 – February 2010
Funding Sponsor: Dana Farber Cancer Institute

E. RESEARCH ACTIVITIES (continued)

Research Grants / Grant Funding (continued):

Completed (continued):

9. “University of Chicago Multi-Institutional Trial: “A Phase III Randomized Trial of Docetaxel-Based Induction Chemotherapy in Patients with N2/N3 Locally Advanced Head and Neck Cancer.”

Role: Institutional Protocol Principal Investigator

University of Southern California Keck School of Medicine

Total Funding: \$53,000.00 (estimated, patient accrual dependent)

Funding Period: November 2004 – 2009

Funding Sponsor: University of Chicago

10. AMGEN Pharmaceuticals: “A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Cancer Receiving Radiotherapy with Concurrent Chemotherapy (RT/CT)”

Role: Institutional Protocol Principal Investigator

University of Southern California Keck School of Medicine

Total Funding: \$60,000 (estimated, patient accrual dependent)

Funding Period: 2005 – 2007

Funding Sponsor: AMGEN

11. Clinical Trial Development Award: “A Phase I/II Trial of Adjuvant Radiation Therapy, Hormonal Therapy and Concurrent Chemotherapy in High Risk Pathologic T3 Prostate Cancer” (W81XWH-05-1-0435)

Role: Principal Investigator

Total Direct Funding: \$99,984

Funding Period: August 1, 2005 – July 31, 2006

Funding Sponsor: Department of Defense (US Army Medical Research and Material Command, Congressionally Directed Medical Research Programs)

12. Department of Energy: “Phase I/II Trial of Neoadjuvant 13-Cis-Retinoic Acid and Alpha-Interferon Prior to 3-D Conformal Radiation Therapy for Unfavorable Localized Adenocarcinoma of Prostate”

Role: Principal Investigator – [Cancer Institute of New Jersey / Gallo Prostate Cancer Center]

Seed Grant Funding: \$20,000 (1 year, Grant DE-FG02-99ER62808)

Funding Period: July 1, 2002 – June 30, 2003

Funding Sponsor: Department of Energy (DOE)

E. RESEARCH ACTIVITIES (*continued*)

Research Grants / Grant Funding (continued):

Completed (continued):

13. Pharmacyclics: “Phase III Randomized Trial of Gadolinium Texaphyrin (PCI-0120) Injection as a Radiation Sensitizer in Patients Receiving Whole Brain Radiation Therapy for the Treatment of Brain Metastases”
Role: Institutional Protocol Principal Investigator
Robert Wood Johnson Medical School / Cancer Institute of New Jersey
Total Funding: \$320,685 (estimated, patient accrual dependent)
Funding Period: 1999 – 2002
Funding Sponsor: Pharmacyclics

14. Aventis Oncology: “Phase I Trial of Docetaxel and Radiation Therapy in the Treatment of Unfavorable Localized Adenocarcinoma of the Prostate”
Role: Principal Investigator -- Investigator Initiated Clinical Trial
Robert Wood Johnson Medical School / Cancer Institute of New Jersey
Total Funding: \$103,352
Funding Period: 1999 – 2003
Funding Sponsor: Aventis Oncology

15. National Cancer Institute (R01): “Targeted Supradose Cisplatin and Radiation Therapy for Stage IV Head and Neck Squamous Cell” Carcinoma: Multi-Institutional Phase II Study” (Radiation Therapy Oncology Group Trial 96-15)
Role: Co-Principal Investigator – Radiation Oncology Chair (10% effort) -- Number 1R01-CA-95-012
Total Funding: \$645,539
Funding Period: 1996 – 2000
Funding Sponsor: National Cancer Institute (NCI)

Invited Reviewer of Grant Study Sections:

1. National Institutes of Health – National Institute of General Medical Sciences
- Institutional Development Award - Program Infrastructure for Clinical and Translational Research (IDeA- CTR)(U54) Applications
--Scientific Panel Member (2020/05 ZGM1 RCB-2IC -- March 6, 2020, Bethesda, MD)

2. National Institutes of Health – National Institute of General Medical Sciences
- Institutional Development Award-CTR (U54) Special Emphasis Scientific Panel Member (April 1, 2019, Washington, D.C.)

E. RESEARCH ACTIVITIES *(continued)*

Invited Reviewer of Grant Study Sections (continued):

3. Department of Defense – United States Army Medical Research and Material Command Congressionally Directed Medical Research Program (DOD-CDMRP)
 - Prostate Can. Res. Prog. (PCRP): Scientific Peer Review Study Section Member: Impact Award-2 (November 13 – 14, 2017, Reston, VA)
4. Department of Defense – United States Army Medical Research and Material Command Congressionally Directed Medical Research Program (DOD-CDMRP)
 - Prostate Can. Res. Prog. (PCRP): Scientific Peer Review Study Section Member: Impact Award-2 (November 18 – 20, 2015, Reston, VA)
5. National Cancer Institute (NCI) -- PAR-13-16 – “NCI Exploratory /Developmental Research Grant Program” -- (NCI Omnibus R21) and PAR-14-007 “NCI Small Grants Program for Cancer Research (NCI Omnibus R03)
 - Meeting ZCA1 RTRB-R M1 S – March 26, 2015
6. Department of Defense – United States Army Medical Research and Material Command Congressionally Directed Medical Research Program (DOD-CDMRP)
 - Prostate Can. Res. Prog.: Scientific Peer Review Study Section Member: Exploration – Hypothesis Development Award (October 2011)
7. Department of Defense – United States Army Medical Research and Material Command Congressionally Directed Medical Research Program (DOD-CDMRP)
 - Prostate Cancer Research Program: Scientific Peer Review Study Section Member: Exploration – Hypothesis Development Award (May 2010)
8. Department of Defense – United States Army Medical Research and Material Command Congressionally Directed Medical Research Program (DOD-CDMRP)
 - Prostate Cancer Research Program: Scientific Peer Review Study Section Member: Prostate Cancer Consortium Award (September 2008)

E. RESEARCH ACTIVITIES (continued)

Invited Ad Hoc Reviewer of Peer Review Journals:

1. International Journal of Radiation Oncology, Biology, and Physics
2. Journal of Medical and Pediatric Oncology
3. Cancer
4. Journal of Clinical Oncology
5. British Journal of Cancer
6. Clinical Cancer Research
7. The Oncologist
8. International Journal of Cancer
9. Cardiovascular and Interventional Radiology

Clinical Trials – Principal Investigator (PI) / Co-PI:

National Clinical Trials:

Cancer and Leukemia Group B (CALGB) – NCI Funded Co-operative Oncology Group

- (1) “Tri-Modality Therapy for Stage IIIA(N₂) Non-Small Cell Lung Cancer: A Phase II Study” – CALGB 8935 - ***Radiation Oncology PI***
- (2) “A Comparison of “Best Local Regional Therapy” With or Without Chemotherapy for Stage IIIA(N₂) Non-Small Cell Lung Cancer: A Randomized Phase III Study” – CALGB 9134 – ***Radiation Oncology Principal Investigator***
- (3) “Treatment of Pathologic Stage C Adenocarcinoma of the Prostate with Adjuvant Radiotherapy – Phase III Randomized Study” – CALGB 9493 – ***Study Principal Investigator***

Radiation Therapy Oncology Group (RTOG)) – NCI Funded Co-operative Oncology Group

- (1) “Phase II Multi-Institutional Trial of Targeted Supradose Cisplatin and Radiation Therapy for Stage IV Squamous Cell Carcinoma of Head and Neck” – RTOG 96-15 – ***Radiation Oncology PI***

E. RESEARCH ACTIVITIES (continued)

Clinical Trials – Principal Investigator (PI) / Co-PI (continued):

Institutional Clinical Trials:

St. Jude Children’s Research Hospital

- (1) “Phase II/III Study of Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia” – *Study Co-PI*
- (2) “Phase II/III Study of Pediatric Patients with Relapsed Non-Hodgkin Lymphoma or T-Cell Acute Lymphoblastic Leukemia” – *Study Co-PI*

University of Tennessee / Veterans Administration Medical Center

- (1) “Utilization of Rapidly Fractionated Radiotherapy in the Definitive Treatment of Non-Metastatic NSCLC: A Phase I/II Study” – *Investigator Initiated Clinical Trial – PI*
- (2) “Phase II Study Using Supradose Intra-Arterial Cisplatin Chemotherapy and Concurrent Radiotherapy for Unresectable Stage III-IV Head and Neck Cancer” (RADPLAT Protocol) – *Investigator Initiated Clinical Trial – Co-PI*
- (3) “Tri-Modality Treatment of Advanced Stage Head and Neck Malignancies with Neoadjuvant High Dose Intra-Arterial Cisplatin and Conventional Radiation Therapy Followed by Surgery” (NEORADPLAT) – *Investigator Initiated Clinical Trial – Co-PI*
- (4) Memphis VA Lung Study 22: “A Phase II Trial of Cisplatin / Taxol with Conventional Radiation Therapy in Stage III Inoperable Non-Small Cell Lung Cancer” – *Investigator Initiated Clinical Trial – PI*

Robert Wood Johnson Medical School / University of Medicine and Dentistry of New Jersey / St. Peter’s University Health Systems

- (1) “Phase I Trial of Docetaxel and Radiation Therapy in the Treatment of Unfavorable Localized Adenocarcinoma of the Prostate” – *Investigator Initiated Clinical Trial – PI (1999 – 2003)*

E. RESEARCH ACTIVITIES (*continued*)

Clinical Trials – Principal Investigator (PI) / Co-PI (continued):

Institutional Clinical Trials (continued):

University of Southern California Keck School of Medicine

- (1) “A Phase I / II Trial of Adjuvant 3-D Conformal Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0M0 Prostate Cancer” – *Investigator Initiated Clinical Trial – PI* [Sept. 2007 – February 2016 (*also continued at KU SOM until August 2015*)]
- (2) “Docetaxel plus 6-Month Androgen Suppression and Radiation Therapy vs. 6-Month Androgen Suppression and Radiation Therapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial” – *Institutional Protocol PI* (2007 – February 2010)

University of Kansas School of Medicine (KU SOM)

- (1) “Phase II Randomized Clinical Trial of 3-D Conformal RT vs IMRT in Post- Prostatectomy Prostate Cancer Patients” - *Investigator Initiated Clinical Trial – PI (funded by Univ. of KS Cancer Center – Large Therapeutic Clinical Trial Award)*
- (2) “M10-897: A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects with Brain Metastases from Non-Small Cell Lung Cancer” – *AbbVie Pharmaceuticals Sponsored Multi-Institutional Clinical Trial – Institutional PI* (2013 – 2014)

National Research Groups – Appointed Leadership Positions, and Invited Committee Memberships:

External Scientific Board Member – National Institute of Health (NIH)

- *NIH Council of Councils for the Environmental Influences on Child Health Outcomes (ECHO)*
March 2017 – Present

NRG Oncology (NCI Funded Co-Operative Oncology Group)

- *Contact Principal Investigator, University of Kansas Cancer Center, a NCI designated Cancer Center*
March 2014 – February 2016

E. RESEARCH ACTIVITIES (*continued*)

National Research Groups – Appointed Leadership Positions, and Invited Committee Memberships (continued):

US Oncology

- *Associate Chair*, Developmental Therapeutics Committee (DTC), June 2011 – February 2016
- *Site Research Leader*, University of Kansas Cancer Center, a NCI designated Cancer Center, July 2012 – February 2016

Radiation Therapy Oncology Group (NCI Funded Co-Operative Group)

- *Principal Investigator*, University of Kansas Cancer Center, a NCI designated Cancer Center, April 2012 – February 2016
- *Member*, July 1990 – February 2016
- *Member*, Head and Neck Cancer Committee, 1998 – 2002

Southwest Oncology Group (NCI Funded Co-Operative Group)

- *Member*, Genitourinary Committee, 2003 – 2016
- *Member*, Lung Cancer Committee, 2003 – 2016
- *Member*, Head and Neck Cancer Committee, 2003 – 2007

Los Angeles Radiological Society (LARS) / Southern California Radiation Oncology Society (SCROS)

- *Member*, Continuing Education Committee (SCROS), March 2007 – February 2008
- *Secretary / Treasurer* (SCROS), August 2007 – July 2008
- *President-Elect* (SCROS), July 2008 – June 2010
- *President* (SCROS), July 2010 – June 2012
- *Member*, LARS/SCROS Midwinter Planning Comm., April 2011 – March 2012

American Radium Society (ARS)

- *Member*, Scientific Program Committee, May 2008 – May 2009

American College of Surgeons Oncology Group (ACOSOG - NCI Funded)

- *Member*, Data Monitoring Committee, August 2005 – December 2008

American Society for Radiation Oncology (ASTRO)

- *Member, State Captain, KS, 2014 – 2015*
- *Member, State Captain Initiative Committee, 2013 – 2014*
- *Member*, Scientific Program Committee, February 1998 – December 2001
- *Member*, Government Relations Committee, 2004 – 2007
- *Member*, Nuclear Regulatory Committee (Government Relations Subcommittee of the Government Relations Council), October 28, 2007 – September 23, 2008

E. RESEARCH ACTIVITIES (continued)

National Research Groups – Appointed Leadership Positions, and Invited Committee Memberships (continued):

American Society of Clinical Oncology (ASCO)

- *Member*, Cancer Education Committee – Head and Neck Cancer Track Team, 2003 – 2006
- *Member*, 1992 – Present

Cancer and Leukemia Group B -- CALGB (NCI Funded Co-Operative Oncology Group)

- *Cadre Member*, Radiation Therapy Quality Assurance Committee, September 1992 – November 1995
- *Cadre Member*, Prostate Committee, 1993 – 1998
- *Cadre Member*, Radiation Oncology Committee, April 1992 – 1998
- *Cadre Member*, Thoracic Surgery Core Committee, 1995 – 1998
- *Cadre Member*, Respiratory Committee, 1996 – 1998
- *Cadre Member*, Membership Committee, 1997 – 1998
- *Cadre Member*, Data and Safety Monitoring Committee, 1999 – 2005

Eastern Co-operative Oncology Group (NCI Funded Co-Operative Oncology Group)

- *Member*, 1998 – 2003

The Academy of Medicine of New Jersey

- *Chair*, Radiation Oncology Section, July 2000 – April 2003
- *Chair*, Head and Neck Oncology Section, July 2000 – Dec. 2002

Veterans Administration National Scientific Advisory

- *Committee Member*, March 1997 – October 1999

Department of Veterans Affairs Southern Region

- *Member*, Advisory Committee, 1992 – October 1995

F. SOCIETY MEMBERSHIPS:

US Oncology Research Group, June 2011 – February 2016

Los Angeles Radiological Society/Southern California Radiation Oncology Society (LARS / SCROS), February 2006 – Present

American Radium Society (ARS), 2005 – Present

The Oncology Society of New Jersey, 1999 – 2003

American Society of Clinical Oncology, 1992 – Present

American Society for Radiation Oncology, 1987 – Present

Tau Beta Pi – National Engineering Honorary Society, 1979

Alpha Chi Sigma – National Chemistry Honorary Society, 1978

G. TEACHING AND MENTORING ACTIVITIES:

1. University of Nevada Las Vegas, School of Medicine
 - a. Taught and gave lecture to 2nd year Medical Students on (1) “Radiation Oncology 101”, and (2) Role of PET Imaging.
 - November 2018
 - b. Taught and gave lecture to UMC Pulmonary & Critical Care Fellows on (1) “Introduction to Clinical Research”
 - August 2019
 - c. Thesis Advisor: Natalie Johns, UNLV Honors College Senior –
 - November 2019 – Present
 - d. Mentoring and Consultation Activities (UNLV Undergraduate Students, UNLV Faculty and UNLV SOM Faculty): 2019 – Present

2. Department of Radiation Oncology, University of Kansas School of Medicine (KU SOM), Kansas City, KS
 - a. Taught and gave lectures as part of the Clinical Didactic Lectures Series to the Radiation Oncology Residents
 - Annually from February 2010 – February 2016
 - b. Initiated and Organized the ***Annual Kansas City-wide “Mock Oral Board Examination”*** for Radiation Oncology Residents in Training from University of Kansas School of Medicine and Other Out-of-Town Board Eligible Candidates
 - Annually from May 2010 – February 2016
 - c. Prepared, Taught and gave lectures to University of Kansas School of Medicine Medical Students as part of the Oncology Module
 - Annually from October 2011 – February 2016
 - d. Participated in the teaching of the KU SOM Medical Oncology Fellows during their Radiation Oncology Rotation
 - Annually from 2012 – February 2016

3. Department of Radiation Oncology, University of Southern California Keck School of Medicine (USC KSOM), Los Angeles, CA
 - a. Taught and gave lectures as part of the Clinical Didactic Lectures Series to the Radiation Oncology Residents
 - Annually from July 2003 – February 2010
 - b. Founded and Initiated the ***Annual Los Angeles City-wide “Mock Oral Board Examination”*** for Radiation Oncology Residents in Training from USC KSOM, Univ. of California at Irvine, Univ. of California Los Angeles, Kaiser Permanente (LA), and Vantage
 - Annually from Spring 2004 – Spring 2009

G. TEACHING ACTIVITIES (continued):

4. Department of Radiation Oncology, Rutgers Robert Wood Johnson Medical School (RWJMS), New Brunswick, NJ
 - a. Taught Annual Clinical Radiation Oncology Didactic Course for Hematology-Oncology Fellows in the Division of Medical Oncology – Organized Course, scheduled other speakers, gave multiple lectures
 - Annually from June 1999 – July 2002
 - b. Organized and Taught annual Lectures in Radiation Oncology (“Introduction to Radiation Oncology,” etc.) to Medical Students at Rutgers - RWJMS
 - July 2000 – April 2003

5. Department of Radiation Oncology, University of Tennessee School of Medicine, Memphis, TN
 - a. Conducted In-Patient Teaching “Rounds” with Hematology-Oncology Fellows at the University of Tennessee, Memphis-VA Medical Center, Memphis, Tennessee
 - Annually from August 1990 – June 1998

6. Department of Radiation Oncology, St. Jude Children’s Research Hospital, Memphis, TN
 - a. Supervised and Taught Rotating Residents from other institutions
 - Annually from August 1990 – June 1996

7. Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia (TJUH), PA
 - a. As Chief Resident, Organized the Weekly “Simon Kramer Didactic Lecture Series” for Radiation Oncology Residents in training at TJUH
 - July 1989 – June 1990
 - b. As Chief Resident, Prepared and Taught Lectures at the Weekly “Simon Kramer Didactic Lecture Series” to the Radiation Oncology Residents in training at TJUH
 - July 1989 – June 1990

H. INVITED SPEAKERSHIPS:

Panels

1. **Best Management of Early Stage Laryngeal Cancer: Radiation Therapy Versus Surgery.** Invited Speaker and Panelist at the Joint Meeting of the American Society for Head and Neck Surgery and the Society of Head and Neck Surgeons: “*Radiation Therapy Is Better than Surgery in the Management of Early Stage Laryngeal Cancer.*” May 14 – 16, 1998 at the Breakers, Palm Beach, Florida.
2. **“Stage III Non-Small Cell Lung Cancer: Is There a Cure Around the Corner? Consensus, Controversies and Emerging Strategies.”** Head Panelist, Moderator and Presenter: “*Can Radiation Therapy Further Improve the Therapeutic Ratio in the Combined Modality Management of Stage III Non-Small Cell Lung Cancer: A Look Into The Past, The Current Outlook, and a Peek Into The Future.*” The American Society of Therapeutic Radiology and Oncology 40th Annual Meeting, October 27, 1998, Phoenix, Arizona.
3. **“New Emerging Therapies in the Treatment of Head and Neck Cancer.”** Invited Panelist and Speaker: “*Can We Improve Survival Rates For Advanced Head and Neck Carcinomas Using Supradose Intra-Arterial Targeted Cisplatin and Concurrent Radiation Therapy?*” The American Society of Therapeutic Radiology and Oncology 40th Annual Meeting, October 28, 1998, Phoenix, Arizona.
4. **Radiation Therapy, Anemia & Outcomes: Current Concepts, Future Strategies, CME Symposium.** Invited Speaker & Panelist: *Impact of Anemia and Tumor Hypoxia in Patients With Head and Neck Cancer.* The 41st Annual American Society for Therapeutic Radiology and Oncology Meeting, October 30, 1999, San Antonio, Texas.
5. **Anemia Y2K: Where Are We Now; Where Are We Going? Clinical Consequences & Treatment Benefits. CME Symposium.** Invited Speaker & Panelist: *Tumor Hypoxia and Anemia: Impact Upon the Efficacy of Radiation Therapy.* The 41st Annual Meeting of the American Society of Hematology, December 3, 1999, New Orleans, Louisiana.
6. **“Management of Early Stage Glottic Cancer.”** Invited Speaker and Panelist: “*Radiation Therapy For Early Stage Glottic Cancer.*” 5th International Conference on Head and Neck Cancer, July 29th – August 2nd, 2000, San Francisco, California.

H. INVITED SPEAKERSHIPS (continued):

Panels (continued)

7. **“Comorbidity as a Predictor.”** Moderator. 5th International Conference on Head and Neck Cancer, July 29th – August 2nd, 2000, San Francisco, California.
8. **Advances in the Treatment of Head and Neck Cancer.** Guest Faculty: *Novel Chemoradiation Strategies and Approaches for Advanced Head and Neck Cancer.* October 30, 2001, Minneapolis, Minnesota.
9. **Cancer Treatment in Developing Countries: The Problems and Opportunities for Clinical Research.** Moderator. *Intensity Modulated Radiotherapy (IMRT) and 3D Conformal RT – Current Perspectives.* American Society of Clinical Oncology Pan Asia Cancer Conference, February 26, 2002, New Delhi, India.
10. **Innovative Strategies in the Management of Advanced Head & Neck Cancer.** Invited Speaker & Panelist for the Los Angeles Radiological Society (LARS) / Southern California Radiation Oncology Society (SCROS) 56th Annual Midwinter Radiology & Radiation Oncology Conference at the Sheraton Universal Hotel, Los Angeles, California on January 23 – 25, 2004.
11. **Options for management of laryngeal cancer.** Invited Panelist for the 110th Annual Meeting at the Combined Otolaryngology Spring Meeting for the Triological Society. April 28, 2007 at the Manchester Grand Hyatt in San Diego, California.
12. **Management of Recurrent Cancer.** Invited Moderator for the 3rd Annual International Head and Neck Cancer Symposium at the University of Southern California Keck School of Medicine, August 3, 2007, University of Southern California Health Sciences Campus in Los Angeles, California.
13. **Head and Neck Cancer.** Invited Moderator for the Los Angeles Radiological Society (LARS) / Southern California Radiation Oncology Society (SCROS) 60th Annual Midwinter Radiology & Radiation Oncology Conference at the Sheraton Universal Hotel, Los Angeles, California, January 26 – 27, 2008.

H. INVITED SPEAKERSHIP (continued):

Panels (continued):

14. **Jatin P. Shah Symposium on Clinical Controversies in Head and Neck Surgery: The Role of the Surgeon in Multidisciplinary Care of Head and Neck Cancer.** Invited Panelist and Lecturer: *Morbidity and Complications of Head and Neck Radiation: When I Need a Surgeon.* 7th International Conference on Head and Neck Cancer, July 19 – 23, 2008, San Francisco, California.
15. **Quality of Life.** Invited Moderator for the 4th Annual International Head and Neck Symposium – “Organ Preservation: Balancing Cure and Quality of Life” at the University of Southern California Keck School of Medicine, July 26, 2008, University of Southern California Health Sciences Campus in Los Angeles, California.
16. **Breast Cancer.** Invited Moderator for the Los Angeles Radiological Society (LARS) / Southern California Radiation Oncology Society (SCROS) 61st Annual Midwinter Radiology & Radiation Oncology Conf. on January 24 – 25, 2009, Universal City, California.
17. **Changing Survival and Functional Outcome.** Invited Moderator for the 5th Annual International Head and Neck Symposium – “Beyond Survivorship: Emerging Technology and Surgical Techniques in the Management and Rehabilitation of Head and Neck Cancer” at the University of Southern California Keck School of Medicine, July 11, 2009, University of Southern California Health Sciences Campus in Los Angeles, California.
18. **Focus on Prostate Cancer.** Invited Moderator for the Los Angeles Radiological Society (LARS) / Southern California Radiation Oncology Society (SCROS) 62nd Annual Midwinter Radiology & Radiation Oncology Conference on January 30 – 31, 2010, Pasadena Convention Center, Pasadena, California.
19. **Bioengineering Colloquium.** Invited Speaker for University of Kansas Bioengineering Colloquium Group. “The Third Revolution: A Perspective of a Radiation Oncologist on the Role of Engineers in finding a Cure for Cancer” at the University of Kansas, January 28, 2011, Lawrence, Kansas.
20. **Focus on Lung Cancer.** Invited Moderator for the Los Angeles Radiological Society / Southern California Radiation Oncology Society 63rd Annual Midwinter Radiation Oncology Conference on February 12 – 13, 2011, Pasadena Convention Center, Pasadena, California.
21. **Prostate Cancer – the Continuum of Care.** Invited Speaker, “New Potential Radiation Therapy Paradigms for the Treatment of Prostate Cancer.” March 8, 2011, Kansas City, Missouri.

H. INVITED SPEAKERSHIP (continued):

Panels (continued):

22. **University of Kansas Hospital Prostate Cancer Program - Prostate Cancer, Know Your Risk, Understand Your Options.** Invited Speaker, “Innovative Radiation Strategies for Prostate Cancer.” April 19, 2011, Kansas City, Kansas.
23. **Gastrointestinal Session.** Invited Moderator for the Los Angeles Radiological Society / Southern California Radiation Oncology Society 64th Annual Midwinter Radiation Oncology Conference on January 21 – 22, 2012, Pasadena Convention Center, Pasadena, California.
24. **First International Symposium on Mathematical and Computational Oncology.** Invited Panelist, “Are genomics really needed and if yes, how comprehensive?”. October 14 – 15, 2019, Lake Tahoe, NV.

National and International Invited Lectures:

1. **Curative Treatment of Pediatric Nasopharyngeal Carcinoma: The 30-Year St. Jude Children’s Research Hospital Experience.** First Mid-South Conference on Head and Neck Cancer, March 30 – April 2, 1995, Peabody Hotel, Memphis, Tennessee.
2. **Combined Modality Treatment of Non-Small Cell Lung Cancer.** Frontiers of Oncology Annual Cancer Conference: Lung Cancer Update at North Shore University Hospital sponsored by Cornell University Medical College, September 18, 1995, Manhasset, New York.
3. **Efficacy of Tri-Modality Therapy in the Treatment of Surgically Staged IIIA (N₂) Non-Small Cell Lung Cancer: Results of Cancer and Leukemia Group B Protocol 8935.** General Hospital of Vienna, Department of Radiation Oncology, October 3, 1995, Vienna, Austria.
4. **Efficacy of Intra-Arterial Targeted Cisplatin and Concurrent Radiation Therapy in the Treatment of Unresectable Stage III-IV Squamous Cell Carcinoma of the Head and Neck Region.** General Hospital of Vienna, Department of Radiation Oncology, October 24, 1995, Vienna, Austria.
5. **Long Term Survival and Neurocognitive Outcome Following Treatment of Isolated CNS Relapse with Craniospinal Irradiation and Additional Chemotherapy in ALL. Results of St. Jude Children’s Research Hospital Trial.** General Hospital of Vienna, Department of Radiation Oncology, October 27, 1995, Vienna, Austria.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

6. **The Role of Radiation Therapy in the Management of Small Cell Lung Cancer.** Multi-Modality Therapy of Chest Malignancies: Update 1996. Sponsored by Harvard Medical School and Brigham and Women's Hospital, March 28-29, 1996, Boston, Massachusetts.
7. **Is Radiation Therapy the Standard of Care for Unresectable Advanced Oropharyngeal Cancer?** Second Mid-South Conference on Head and Neck Cancer: Organ Preservation, Function and Rehabilitation, April 19 – 21, 1996 at Peabody Hotel, Memphis, Tennessee.
8. **The Role of Thoracic and Prophylactic Cranial Irradiation In the Management Of Small Cell Lung Cancer.** “Visiting Professor” at the University of Kentucky Radiation Oncology Department, August 15, 1996, Lexington, Kentucky.
9. **Combined Modality Therapies for Stage III Non-Small Cell Lung Cancer.** “Visiting Professor” at the University of Kentucky Radiation Oncology Department, August 16, 1996, Lexington, Kentucky.
10. **The Role of Radiation Therapy in the University of Tennessee, Memphis-Genitourinary Oncology Program.** Presented at the University of Tennessee, College of Medicine Alumni Council Meeting, October 3, 1996 at Adam's Mark Hotel, Memphis, Tennessee.
11. **The Role of Radiation Therapy in the Combined Modality Treatment of Advanced Non-Small Cell Lung Cancer.** Invited speaker at Second Annual Veterans Administration National Cancer Symposium: Multidisciplinary Approaches to Cancer Care in the 21st Century, October 24, 1997 at Hyatt Regency Hotel, San Antonio, Texas.
12. **The Role of the Radiation Oncologist: Care of the Dying Lung Cancer Patient.** Invited speaker at the 63rd Annual Scientific Assembly of the American College of Chest Physicians, October 26 – 30, 1997, Ernest N. Morial Convention Center, New Orleans, Louisiana.
13. **The Role of Radiation Therapy in the Management of Locally Advanced Non-Small Cell Lung Cancer: Current Standard of Practice and Future Directions.** “Visiting Professor” at Baylor College of Medicine/Methodist Hospital, March 26, 1998, Houston, Texas.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

14. **The Role of Radiation Therapy in the Management of Small Cell Lung Cancer: Back to the Future!** “Visiting Professor” at Baylor College of Medicine/Methodist Hospital, March 26, 1998, Houston, Texas.
15. **The Role of Radiation Therapy in the Management of Advanced Head and Neck Cancer: Use of Intra-Arterial Cisplatin and Radiation Therapy.** Oral Cancer Symposium, Woodbridge Hilton, September 23, 1998, Iselin, New Jersey.
16. **The Role of Thoracic Radiation Therapy in the Management of Non-Small Cell Lung Cancer. Multi-Disciplinary Treatment of Lung Cancer:** Sierra Medical Center Symposium, September 26, 1998, Cliff Inn, El Paso, Texas.
17. **The Role of Radiation Therapy in the Management of Non-Small Cell Lung Cancer. Lung Cancer '98:** Jacksonville Memorial Hospital, October 3, 1998, Jacksonville, Florida.
18. **Multi-Disciplinary Lung Cancer Management.** Munson Medical Center, October 22, 1998, Traverse City, Michigan.
19. **The Use of Intra-Arterial Cisplatin and Concurrent Radiation Therapy in the Management of Unresectable Advanced Head and Neck Squamous Cell Carcinoma: Feasibility, Efficiency and Long Term Outcome.** The Academy of Medicine of New Jersey, Head and Neck Oncology, October 21, 1998, The Manor, West Orange, New Jersey.
20. **Innovations in Radiation Oncology.** WCTC Radio 1450 AM Fall Health Forum, November 21, 1998, Holiday Inn, Somerset, New Jersey.
21. **The Role of Radiation Therapy in the Management of Non-Small Cell Lung Cancer: Can We Make a Difference?** University of Maryland, December 4, 1998, Baltimore, Maryland.
22. **Locally Advanced Non-Small Cell Lung Cancer: Is There a Cure Around The Corner? Consensus, Controversies, and Emerging Strategies.** Twenty – Seventh Annual Joint Conference of the American Thoracic Society, New Jersey Thoracic Society and The New Jersey Chapter of the American College of Chest Physicians, Hyatt Regency, March 5, 1999, New Brunswick, New Jersey.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

23. **Direct Correlative Relationship between Initial Hemoglobin Levels and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer and Head and Neck Cancer.** Ortho Biotech Inc. Radiation Therapy Advisory Board Meeting, March 4 – 5, 1999, The Pierre Hotel, New York, New York.
24. **Conformal Radiation Therapy for Prostate Cancer.** Ninth Annual Advances In Urology, University of South Florida College of Medicine and the H. Lee Moffit Cancer Center and Research Institute, April 10, 1999, Key West, Florida.
25. **Bladder Sparing Strategies for Invasive Bladder Cancer.** Ninth Annual Advances In Urology, University of South Florida College of Medicine and the H. Lee Moffit Cancer Center and Research Institute, April 10, 1999, Key West, Florida.
26. **Innovative Combined Modality Therapeutic Approaches To The Management Of Advanced Head & Neck Malignancies.** Medical Grand Rounds, Raritan Bay Medical Center, May 25, 1999, Perth Amboy, New Jersey.
27. **Five-Year Outcome Analyses of the Treatment of Stage III-IV Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Using Supradose Intra-Arterial Targeted Cisplatin (SIT-P) and Radiation Therapy (RT).** The 1999 Annual Retreat on Cancer Research in New Jersey, The Cancer Institute of New Jersey and The New Jersey State Commission on Cancer Research, May 27, 1999, New Brunswick, New Jersey.
28. **Combined Modality Treatment of Locally Advanced Non-Small Cell Lung Cancer: Same Old, Same Old, or Is There Anything New.** Mayo Clinic, July 8, 1999, Jacksonville, Florida.
29. **The Role of Radiation Therapy in the Combined Modality Treatment of Malignant Diseases.** Third Annual Wilentz Lecture, Raritan Bay Medical Center, October 26, 1999, Perth Amboy, New Jersey.
30. **The Combined Modality Treatment of Rectal Cancer.** Muhlenberg Hospital, July 27, 1999, Plainfield, New Jersey.
31. **The ChemoRadiation Therapy Treatment of Non-Small Cell Lung Cancer.** February 17, 2000, Sarasota, Florida.
32. **The Tri-Modality Treatment of Non-Small Cell Lung Cancer.** Blake Medical Center, February 18, 2000, Bradenton, Florida.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

33. **The Combined Modality Treatment of Non-Small Cell Lung Cancer.** State University of New York-Brooklyn, Veterans Administration Medical Center, April 4, 2000, Brooklyn, New York.
34. **The Combined Modality Management of Head & Neck Cancer.** The Brookdale University Hospital and Medical Center, May 8, 2000, Brooklyn, New York.
35. **The ChemoRadiation Treatment of Non-Small Cell Lung Cancer: "Same Old, Same Old Or Is There Anything New."** August 23, 2000, Tampa, Florida.
36. **The Combined Modality Treatment of Advanced Head and Neck Cancer.** Raritan Bay Medical Center, September 19, 2000, Perth Amboy, New Jersey.
37. **Small Cell Lung Cancer: A Paradigm For The Integration Of Radiation Therapy With Chemotherapy--Why Thoracic Radiation Therapy And Prophylactic Cranial Irradiation Improved Survival.** ChemoRadiation Summit 2000, September 22, 2000, Yosemite, California.
38. **3-D Conformal Radiation Therapy for Localized Prostate Cancer.** American College of Surgeons, New Jersey Chapter, December 2, 2000, Princeton, New Jersey.
39. **The Combined Modality Management of Head and Neck Cancer.** Thomas Jefferson Medical College, December 20, 2000, Philadelphia, Pennsylvania.
40. **The Combined Modality Management of Advanced Head and Neck Squamous Cell Carcinoma.** University of Florida, February 7, 2001, Gainesville, Florida.
41. **Analysis of Survival Outcome and Prognostic Factors in the Treatment of Unresectable Head and Neck Squamous Cell Carcinoma Using Supradose Intra-Arterial Cisplatin and Concurrent Radiation Therapy.** University of Florida, February 8, 2001, Gainesville, Florida.
42. **The Management of Locally Advanced Head and Neck Squamous Cell Carcinoma with Intra-arterial Cisplatin and Concurrent Radiation Therapy: "The RADPLAT Protocol."** Grand Rounds, Morristown Memorial Hospital, February 22, 2001, Morristown, New Jersey.
43. **Impact of Anemia Upon Patients Undergoing Radiation Therapy.** March 15, 2001, Quebec City, Quebec, Canada.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

44. **Tumor Hypoxia and Anemia: Impact Upon the Efficacy of Radiation Therapy in the Treatment of Solid Tumors.** Montreal Botanical Garden, March 17, 2001, Montreal, Quebec, Canada.
45. **Anemia and Radiation Therapy: Impact Upon Clinical Outcome.** Different Aspects of Pain and New Areas of Oncology: Rendezvous 2001, Manoir des Sables, March 18, 2001, Orford, Canada.
46. **ChemoRadiation Treatment of Non-Small Cell Lung Cancer.** Grand Rounds, Raritan Bay Medical Center, March 27, 2001, Perth Amboy, New Jersey.
47. **Radiographic Changes in Lung of Patients Treated with Stereotactic Ablative Body Radiation Therapy: Low-Dose Volumes as the Driving Force for Radiographic Change.** The University of Kansas Medical Center, August 10, 2015, Kansas City, Kansas.
48. **Impact of Anemia on Patients with Locally Advanced Head and Neck Cancer Treated with RADPLAT Protocol Therapy.** Ortho Biotech Inc., August 2, 2001, Raritan, New Jersey.
49. **Tumor Hypoxia and Anemia: Impact Upon the Efficacy of Radiation Therapy in the Treatment of Head and Neck Cancer.** University of Southern California / Norris Comprehensive Cancer Center, August 22, 2001, Los Angeles, California.
50. **Tumor Hypoxia and Anemia: Impact Upon the Efficacy of Radiation Therapy in the Treatment of Solid Tumors.** August 22, 2001, Beverly Hills, California.
51. **Impact of Anemia on the Efficacy of Radiation Therapy.** University of California, Los Angeles, August 23, 2001, Los Angeles, California
52. **Relationship between Anemia and Efficacy of Radiation Therapy.** City of Hope National Medical Center, August 23, 2001, Los Angeles, California.
53. **New Directions in Radiation Oncology: Strategies and Technologies.** 5th Annual Wilentz Lecture, Raritan Bay Medical Center, October 9, 2001, Perth Amboy, New Jersey.
54. **Management of Locally Advanced Head and Neck Carcinoma: Innovative Organ Preservation Strategies.** Gulf Coast Cancer Treatment Center, October 24, 2001, Panama City, Florida.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

55. **The Effect of Anemia on Locally Advanced Head and Neck Cancer Patients Treated with ChemoRadiation Therapy: Management Implications.** The University of Kansas Medical Center, January 17, 2002, Kansas City, Kansas.
56. **New Paradigms in the Treatment of Localized Prostate Cancer: Radiosensitization with Docetaxel and Concurrent 3-D Conformal Radiation Therapy.** JFK Medical Center, June 10, 2002, Edison, New Jersey.
57. **Management of Anemia: Therapeutic Implications.** St. Mary's Hospital, June 26, 2002, Jefferson City, Missouri.
58. **Novel Strategies for Treating High Risk Prostate Cancer.** Medical Grand Rounds, Raritan Bay Medical Center, September 3, 2002, Perth Amboy, New Jersey.
59. **Treatment Options for Prostate and Cervical Cancers.** Maximizing Oncologic Therapy: New Developments in Chemotherapeutics, Radiotherapeutics, and Adjunctive Care. October 9, 2002, San Francisco, California.
60. **Anemia and Radiation Therapy – Maximizing Clinical Outcomes.** Maximizing Oncologic Therapy: New Developments in Chemotherapeutics, Radiotherapeutics, and Adjunctive Care. October 9, 2002, San Francisco, California.
61. **Treatment Options for Prostate and Cervical Cancers.** Maximizing Oncologic Therapy: New Developments in Chemotherapeutics, Radiotherapeutics, and Adjunctive Care. October 12, 2002, Chicago, Illinois.
62. **Anemia and Radiation Therapy – Maximizing Clinical Outcomes.** Maximizing Oncologic Therapy: New Developments in Chemotherapeutics, Radiotherapeutics, and Adjunctive Care. October 12, 2002, Chicago, Illinois.
63. **The Combined Modality Treatment of Advanced Non-Small Cell Lung Cancer: Strategies and the Impact of Anemia.** Toronto Sunnybrook Regional Cancer Centre, November 28, 2002, Toronto, Ontario, Canada.
64. **Advances in Chemoradiation Strategies for Prostate Cancer.** St. Vincent's Medical Center, December 10, 2002, Staten Island, New York.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

65. **Radiosensitization with Docetaxel and Concurrent 3-D Conformal Radiation Therapy: Results of a Phase I Trial.** Lahey Clinic, January 23, 2003, Burlington, Massachusetts.
66. **Symposia: New Frontiers in the Treatment of High Risk Prostate Cancer. New Paradigms in the Treatment of Unfavorable Prostate Cancer: Radiosensitization with Docetaxel.** Ronald B. Herberman Conference Center, Hillman Cancer Pavilion, University of Pittsburgh Medical Center, February 12, 2003, Pittsburgh, Pennsylvania.
67. **The Combined Modality Treatment of Advanced NSCLC: Strategies and the Impact of Anemia.** Cancer Care Manitoba, March 24, 2003, Winnipeg, Manitoba, Canada.
68. **The Combined Modality Treatment of Advanced Head and Neck Cancer: The Impact of Anemia.** Cancer Care Manitoba, March 25, 2003, Winnipeg, Manitoba, Canada.
69. **The Impact of Anemia on the Combined Modality Treatment of NSCLC.** Tom Baker Cancer Center, March 26, 2003, Calgary, Alberta, Canada.
70. **The Role of Radiation Therapy in the Management of NSCLC: The Adverse Effect of Anemia.** Saskatoon Cancer Agency, March 26, 2003, Saskatoon, Canada.
71. **Management of Advanced Head and Neck Cancer with Intra-Arterial Cisplatin and Radiation Therapy – The RADPLAT Protocol: The Impact of Anemia on Local Control and Survival.** Cross Cancer Center, March 27, 2003, Edmonton, Canada.
72. **A Novel Strategy for the Treatment of High Risk Prostate Cancer: Docetaxel Radiosensitization.** Symposium: Combining Forces – Joining Urologists and Medical Oncologists to Optimize Treatment for Advanced Prostate Cancer. The Ritz Carlton Palm Beach, March 29, 2003, Palm Beach, Florida.
73. **Management of High Risk Prostate Cancer: Radiosensitization with Taxanes.** South Carolina Oncology Society. Innovations in Oncology, September 6, 2003, Charleston, South Carolina.
74. **The Combined Modality Management of Head and Neck Cancer & Non-Small Cell Lung Cancer: The Necessity for Radioprotection.** Huntsville Memorial Hospital, January 15, 2004, Huntsville, Alabama.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

75. **The Management of Advanced Head and Neck Cancer: The Rationale for Cytoprotection.** University of Alabama Birmingham Hospital, January 16, 2004, Birmingham, Alabama.
76. **Targeted Intra-Arterial Chemotherapy and Concurrent Radiation Therapy for Advanced Head and Neck Cancer.** The 10th Annual Aichi Cancer Center International Symposium. February 14, 2004, Nagoya, Japan.
77. **Radiation Oncology – What the Primary Care Physician Needs to Know.** The 30th Annual Review Course, Common Problems in Primary Care – 2004. University of Southern California. March 9, 2004, Los Angeles, California.
78. **Innovations in Radiation Oncology in the Treatment of Gastrointestinal Malignancies.** Colorectal Cancer Treatment: The Office Team Approach. University of Southern California, March 13, 2004, Los Angeles, California.
79. **First Annual ASCO/ASTRO Multidisciplinary Prostate Cancer Symposium.** Current Status and Future Directions for Prevention and Management 2005. Integration of Concurrent Chemotherapy with Radiation Therapy in Localized High Risk Prostate Cancer. The Hyatt Grand Cypress Hotel, February 18, 2005, Orlando, Florida.
80. **Innovative Approaches in the Combined Modality Management of Non-Small Cell Lung Cancer.** Controversies in Lung Cancer: Diagnostic and Treatment Trends 2005. The Waterfront Hilton Hotel, September 20, 2005, Huntington Beach, California.
2006 Cytoprotection Institute for Education: Continuing Medical Education for the Cancer Care Team. “The Management of Advanced Head/Neck and Non-Small Cell Lung Cancer.” Methodist Hospital, July 29, 2006, Des Moines, Iowa.
81. **2nd Annual International Head and Neck Symposium.** “Advances in Radiation Oncology.” Mayer Medical Teaching Center, Keith Administration Building, Health Sciences Campus, University of Southern California / Keck School of Medicine, August 4, 2006, Los Angeles, California.
82. **The International Workshop on Intra-arterial Chemotherapy for Head and Neck Cancer.** Panel Discussion: Choosing a Chemoradiation Protocol “Prognostic Factors in Advanced Head/Neck Cancer Patients Treated with Chemoradiation Therapy.” Conference Center, Prairie Heart Institute at St. John’s Hospital, August 20-22, 2006, Springfield, Illinois.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

83. **Radiation Management of Recurrent Head and Neck Cancer.** Invited speaker for the 3rd Annual International Head and Neck Cancer Symposium at the University of Southern California - Keck School of Medicine, August 3, 2007, University of Southern California Health Sciences Campus in Los Angeles, California.
84. **Integrating Targeted Therapies and Biologic Agents in the Combined Modality Management of Advanced HNSCC.** Invited speaker for the 4th Annual International Head and Neck Symposium at the University of Southern California - Keck School of Medicine, July 26, 2007, University of Southern California Health Sciences Campus in Los Angeles, California.
85. **Advances in Radiation Therapy for Oral Cancer.** Invited speaker for the University of Southern California International Oral Medicine Symposium at the University of Southern California - School of Dentistry, November 22, 2008, University Park Campus in Los Angeles, California.
86. **Controversies in Management of Locally and Advanced Head and Neck Cancer: Surgery vs. Non-Surgical Approaches, Induction vs. Concurrent Chemoradiation Therapy, and the Role of Biologic Agents.** Invited speaker for the Los Angeles Radiological Society (LARS) / Southern California Radiation Oncology Society (SCROS) 61st Annual Midwinter Radiology & Radiology Oncology Conference on January 24 – 25, 2009 at the Sheraton Universal Hotel, Universal City, California.
87. **Cyberknife for Head and Neck Cancer.** Invited speaker for the 5th Annual International Head and Neck Symposium at the University of Southern California - Keck School of Medicine, July 11, 2009, University of Southern California Health Sciences Campus in Los Angeles, California.
88. **New Potential Radiation Therapy Paradigms for the Treatment of High Risk Prostate Cancer: Chemotherapy Radiosensitization.** Invited Keynote Address for the Platinum Jubilee Celebration at the Ida B. Scudder Cancer Center, Department of Radiation Oncology, January 10, 2014, Christian Medical College, Vellore, India.
89. **The Evolution of the Management of Locally Advanced Head and Neck Cancer: “Same Old, Same Old, or Is There Anything New?”** Invited Distinguished Speaker, International Head and Neck Cancer Session, 54th Annual Japanese Society of Clinical Oncology, October 22 - 29, 2016, Yokohoma, Japan.

H. INVITED SPEAKERSHIP (continued):

National and International Invited Lectures (continued):

90. **Building the Medical Community.** The Atlantic Cancer and the Community. The Smith Center. September 20, 2017, Las Vegas, Nevada.
91. **The Mountain West (MW) Clinical and Translational Research – Infrastructure Network (CTR-IN) Program: Facilitating Increased Collaboration Among the MW IDeA Programs.** 2017 IDeA Western Regional Conference. October 20, 2017, Jackson Hole, Wyoming.
92. **Orientation to the Mountain West Clinical and Translational Infrastructure Network Program.** Idaho State University – Annual Kasiska Division of Health Science Opening Faculty Assembly, September 7, 2018, Meridian, Idaho.
93. **The Mountain West Clinical and Translational Research – Infrastructure Network Program: The Past, the Present and the Future.** 3rd Annual Nevada Institutional Development Award (IDeA) / SfN COBRE Neurodegeneration and Translational Neuroscience (CNTN) Conference, November 9, 2018, SWITCH Headquarters, Las Vegas, Nevada.
94. **American Cancer Society – Cancer Action Network.** Invited Speaker for the 8th Annual Las Vegas Policy Forum: Cancer Control in Nevada. “Establishing a Research Culture and infrastructure at a New Medical School: The UNLV School of Medicine Experience” at Roseman University Summerlin Campus, August 21, 2019, Henderson, Nevada.
95. **University of Montana – School of Public and Community Health.** Invited Speaker for the School of Public and Community and Health Sciences Faculty. “Pilot Funding and Professional Development Support for Clinical and Translational Research” at University of Montana, September 10, 2019, Missoula, Montana.
96. **Western IDeA Regional Meeting.** Invited Speaker “The Impact of the Clinical Translational Research Infrastructure (MW CTR-IN) Program on the Research Capacity and Infrastructure of the Mountain West Universities” at Rio All Suites Hotel & Casino, October 8, 2019 in Las Vegas, Nevada.
97. **Western IDeA Regional Meeting.** Invited Speaker “Overview of the Mountain West CTR-IN Program” at Rio All Suites Hotel & Casino, October 9, 2019 in Las Vegas, Nevada.
98. **First International Symposium on Mathematical and Computational Oncology.** Invited Speaker “Chemotherapy Radiosensitization for High Risk Prostate Cancer: From Concept to Clinical Trial to Changing the Standard of Care”, October 14 - 15, 2019, Lake Tahoe, NV.

H. INVITED SPEAKERSHIP (continued):

Presentations at Major National and International Meetings (as Presenter and / or First Author):

1. **Oral presentation** at the **33rd Annual American Society for Therapeutic Radiology and Oncology Meeting**, Washington, DC, November 4 – 8, 1991. **Kumar P**, et al. *Factors Associated with Outcome Following Isolated Meningeal Relapse Treated with Craniospinal Irradiation in Childhood Acute Lymphoblastic Leukemia.*
2. **Oral presentation** at the **34th Annual American Society for Therapeutic Radiology and Oncology Meeting**, San Diego, California, November 9 – 13, 1992. **Kumar P**, et al. *Outcome with Central Nervous System Involvement at Diagnosis in Childhood Acute Nonlymphoblastic Leukemia.*
3. **Oral presentation** at the **35th Annual American Society for Therapeutic Radiology and Oncology Meeting**, New Orleans, Louisiana, October 11-15, 1993. **Kumar P**, et al. *A Prospective Neuropsychological Evaluation of Children Treated with Additional Chemotherapy and Craniospinal Irradiation (CSI) Following Central Nervous System (CNS) Relapse in Acute Lymphoblastic (ALL).*
4. **Oral presentation** at the **36th Annual American Society for Therapeutic Radiology and Oncology Meeting**, San Francisco, California, October 1994. **Kumar P**, et al. *Efficacy and Safety of Tri-Modality Treatment in Patients with Pathologically Staged IIIA(N₂) Non-Small Cell Lung Cancer (NSCLC) Utilizing Consolidative Thoracic Irradiation: Results of Cancer and Leukemia Group B (CALGB) Trial 8935.*
5. **Oral presentation** at the **Evolving Role of Radiation Therapy in Pediatric Oncology Meeting**, sponsored by the **University of Pennsylvania School of Medicine**, Philadelphia, Pennsylvania, January 19 – 21, 1995. **Kumar P**, et al. *Gender Based Differences in Neurocognitive Outcome Following Treatment of Isolated Central Nervous System (CNS) Relapse with Additional Chemotherapy (CT) and Craniospinal Irradiation (CSI) in Acute Lymphoblastic Leukemia (ALL).*
6. **Oral presentation** at the **American Radium Society Meeting** in Paris, France, April 29 – May 3, 1995. **Kumar P**, et al. *Patterns of Relapse Following Tri-Modality Treatment in Patients with Pathologically Staged IIIA (N₂) Non-Small Cell Lung Cancer (NSCLC): Analysis of Cancer and Leukemia Group B (CALGB) Protocol 8935.*

H. INVITED SPEAKERSHIP (continued):

Presentations at Major National and International Meetings (as Presenter and / or First Author -- continued):

7. **Oral presentation** at the **31st Annual American Society of Clinical Oncology Meeting**, Los Angeles, California, May 20 – 23, 1995. **Kumar P**, et al. *Long Term Survival and Neurocognitive Outcome Following Isolated Central Nervous System (CNS) Relapse in Childhood Acute Lymphoblastic Leukemia (ALL).*
8. **Oral presentation** at the **37th Annual American Society for Therapeutic Radiology and Oncology Meeting**, Miami Beach, Florida, October 8 – 11, 1995. **Kumar P**, et al. *Efficacy of Supradose Intra-Arterial Targeted (SIT) Cisplatin (P) and Concurrent Radiation Therapy (RT) in the Treatment of Unresectable Stage III-IV Head and Neck (H/N) Carcinoma.*
9. **Poster presentation** at the **8th European Cancer Conference** in Paris, France, October 29 – November 2, 1995. **Kumar P**, et al. *Treatment of Unresectable Stage III-IV Head and Neck (N/N) Carcinoma Using Intra-Arterial Targeted (SIT) Cisplatin (P) and Concurrent Radiation Therapy (RT).*
10. **Poster presentation** at the **38th Annual American Society for Therapeutic Radiology and Oncology Meeting**, Los Angeles, California, October 27 – 30, 1996. **Kumar P**, et al. *Feasibility of Accelerated Radiotherapy (AR) Using a Concomitant Boost for the Treatment of Unresectable Non-Small Cell Lung Cancer (NSCLC): A Phase II Study.*
11. **Poster presentation** at the **38th Annual American Society for Therapeutic Radiology and Oncology Meeting**, Los Angeles, California, October 27 – 30, 1996. **Kumar P**, et al. *Does the Quality of Radiation Therapy (RT) Impact Upon Outcome in the Tri-Modality Treatment of Stage IIIA (N₂) Non-Small Cell Lung Cancer (NSCLC)?: Analysis of Cancer and Leukemia Group B (CALGB) Protocol 8935.*

H. INVITED SPEAKERSHIP (continued):

Presentations at Major National and International Meetings (as Presenter and / or First Author -- continued):

12. **Poster presentation** at the **15th Annual European Society for Therapeutic Radiology and Oncology Meeting**, Vienna, Austria, September 23 – 26, 1996. **Kumar P**, et al. *Feasibility of Accelerated Radiotherapy (AR) Using a Concomitant Boost in the Treatment of Unresectable Non-Small Cell Lung Cancer (NSCLC): A Phase II Study.*
13. **Poster presentation** at the **15th Annual European Society for Therapeutic Radiology and Oncology Meeting**, Vienna, Austria, September 23 – 26, 1996. **Kumar P**, et al. *Analysis of Prognostic Factors (PF) in the Treatment of Unresectable Stage III-IV Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Using Supradose Intra-Arterial Targeted Cisplatin (SIT-P) and Concurrent Radiation Therapy (RT).*
14. **Oral presentation** at the **33rd Annual American Society of Clinical Oncology Meeting**, May 17 – 20, 1997, Denver, Colorado. **P Kumar**, et al. *Long Term Outcome Following Curative Therapy of Pediatric Nasopharyngeal Carcinoma (PNC): Three Decade Experience at St. Jude Children's Research Hospital (SJCRH).*
15. **Poster discussion presentation** at the **33rd Annual American Society of Clinical Oncology Meeting**, May 17 – 20, 1997, Denver, Colorado. **P Kumar**, et al. *Analysis of Survival Outcome and Prognostic Factors (PF) in the Treatment of Unresectable Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Using Supradose Intra-Arterial Targeted Cisplatin (SIT-P) and Concurrent Radiation Therapy (RT).*
16. **Oral presentation** at the **39th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology**, October 19 – 22, 1997, Orlando, Florida. **P Kumar**, et al. for CALGB. *Comparison of Pre-Operative Thoracic Radiation Therapy (TRT) to Pre-Operative Chemotherapy (CT) in Surgically Staged IIIA(N₂) Non-Small Cell Lung Cancer (NSCLC): Initial Results of Cancer and Leukemia Group B (CALGB) Phase III Protocol 9134.*
17. **Poster presentation** at the **40th Annual American Society for Therapeutic Radiology and Oncology Meeting**, October 25 – 29, 1998, Phoenix, Arizona. **P Kumar**, et al. *The Impact of Radiation Related Factors Upon Long Term Outcome in the Management of Advanced Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Treated With Supradose Intra-Arterial Targeted (SIT) Cisplatin (P) and Radiation Therapy (RT).*

H. INVITED SPEAKERSHIP (continued):

Presentations at Major National and International Meetings (as Presenter and / or First Author -- continued):

18. **Poster presentation** at the **35th Annual American Society of Clinical Oncology Meeting**, May 15 – 18, 1999, Atlanta, Georgia. **P Kumar**, et al. *Five Year Outcome Analyses Following Treatment of Stage III/IV Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Using Supradose Intra-Arterial Targeted Cisplatin (SIT-P) and Concurrent Radiation Therapy (RT).*
19. **Poster discussion presentation** at the **41st Annual American Society for Therapeutic Radiology and Oncology Meeting**, October 31 – November 4, 1999, San Antonio, Texas. **P Kumar**, et al. *The Prophylactic Use of Pentoxifylline in the Therapy of Stage IV-N_{2,3} Head & Neck (H/N) Squamous Cell Carcinoma (SCCa) Treated with Supradose Intra-arterial Targeted Cisplatin (SIT-P) and Concurrent Radiation Therapy (RT): Preliminary Results of a Pilot Study.*
20. **Poster presentation** at the **36th Annual Meeting of the American Society of Clinical Oncology**, May 20 – 23, 2000, New Orleans, Louisiana. **P Kumar**, et al. *Long Term Survival Outcome of a Sequential Trimodality Trial in Pathologically Staged IIIA (N2) Non-Small Cell Lung Cancer (NSCLC): Final Results of Cancer and Leukemia Group B Protocol (CALGB) Protocol 8935.*
21. **Oral presentation** at the **5th International Conference on Head and Neck Cancer**, July 29 – August 2, 2000, San Francisco, California. **P Kumar**, et al. *Pre-Treatment Hemoglobin (HGB) Level is a Significant Predictor of Response Rates (RR) and Survival in State III/IV Head and Neck (H/N) Squamous Cell Carcinoma (SCCA) Treated with Intra-Arterial (IA) Cisplatin and Radiation Therapy (RT).*
22. **Oral presentation** at the **42nd Annual American Society of Therapeutic Radiology and Oncology Meeting**, October 22 – 26, 2000, Boston, Massachusetts. **P Kumar**, et al. *The Feasibility of Using Intra-Arterial Cisplatin & Radiation Therapy for State IV-T4 Head/Neck (H/N) Squamous Cell Carcinoma in a Multi-Institutional Setting: Preliminary Results of Radiation Therapy Oncology Group (RTOG) Trial 9615.*

H. INVITED SPEAKERSHIP (continued):

Presentations at Major National and International Meetings (as Presenter and / or First Author -- continued):

23. **Oral presentation** at the **42nd Annual American Society of Therapeutic Radiology and Oncology Meeting**, October 22 – 26, 2000, Boston, Massachusetts. **P Kumar**, et al. *The Feasibility of Using Intra-Arterial Cisplatin & Radiation Therapy for Stage IV-T4 Head/Neck (H/N) Squamous Cell Carcinoma in a Multi-Institutional Setting: Preliminary Results of Radiation Therapy Oncology Group (RTOG) Trial 9615.*
24. **Poster discussion** at the **37th Annual Meeting of the American Society of Clinical Oncology**, May 11 – 15, 2001, San Francisco, California. **P Kumar**, et al. *Supradose Intra-Arterial Cisplatin And Concurrent Radiation Therapy For The Treatment Of Stage IV-T4 Head And Neck Squamous Cell Carcinoma Is Feasible And Efficacious In A Multi-Institutional Setting: Initial Results Of Radiation Therapy Oncology Group Trial 9615.*
25. **Poster presentation** at the **38th Annual Meeting of the American Society of Clinical Oncology**, May 18 – 21, 2002, Orlando, Florida. **P Kumar**, et al. *A Novel Therapeutic Strategy Testing the Safety and Feasibility of Concurrent Docetaxel and 3-D Conformal Radiation Therapy (RT) in Patients with High Risk Localized Adenocarcinoma of the Prostate: Progress Report of an On-Going Phase I Trial.*
26. **Poster discussion presentation** at the **44th Annual Meeting of the American Society of Therapeutic Radiology and Oncology**, October 6 – 10, 2002, New Orleans, Louisiana. **P Kumar**, et al. *The Safety And Feasibility Of Concurrent Docetaxel And 3-D Conformal Radiation Therapy (3-D CRT) In Patients With High Risk Localized Adenocarcinoma Of The Prostate: Preliminary Report Of An On-Going Phase I Trial.*
27. **Poster presentation** at the **39th Annual Meeting of the American Society of Clinical Oncology**, May 31 – June 3, 2003, Chicago, Illinois. **P Kumar**, et al. *The Safety Of Concurrent Docetaxel And 3-D Conformal Radiation Therapy (CRT) In Patients With High Risk Localized Adenocarcinoma Of The Prostate: Results Of A Completed Phase I Trial.*
28. **Oral presentation** at the **45th Annual American Society of Therapeutic Radiology and Oncology Meeting**, October 19 – 23, 2003, Salt Lake City, Utah. **P Kumar**, et al. *Motexafin Gadolinium (MGd) Overcomes Adverse Survival Effect of Anemia in Brain Metastases (BM) Patients Treated with Whole Brain Radiation Therapy (WBRT): Analysis of a Phase III Randomized Trial.*

H. INVITED SPEAKERSHIP (continued):

Presentations at Major National and International Meetings (as Presenter and / or First Author -- continued):

29. **Poster Discussion Presentation** at the **40th Annual Meeting of the American Society of Clinical Oncology**, June 4 – 8, 2004, New Orleans, Louisiana. **P Kumar**, et al. *Outcome Comparisons of Four Radiation Therapy Oncology Group Trials in Patients with Stage IV-T4 Head and Neck Cancer: Encouraging Results Using Intra-Arterial Cisplatin and Radiation Therapy.*
30. **Poster Presentation** at the **46th Annual American Society of Therapeutic Radiology and Oncology Meeting**, October 1 – 6, 2004, New Orleans, Louisiana. **P Kumar**, et al. *Comparison of Intra-Arterial Cisplatin and Radiation Therapy (RT) to Other Radiation Therapy Oncology Group (RTOG) Regimens Using Standard or Accelerated RT With or Without Concurrent Chemotherapy in Patients with Stage IV-T4 Head and Neck Cancer.*
31. **Poster Presentation** at the **European Society for Therapeutic Radiology Oncology, ESTRO 23**, October 24 – 29, 2004, Amsterdam, Netherlands. **P Kumar**, CK Hill. *In Vitro Biological Effects of 13-Cis-Retinoic Acid (CRA) & Interferon-Alpha (IFN) combination with or without Radiation more selectively Down Regulates BCL-2 and Increases Apoptosis in Prostate Tumor Cells (LnCAP) than in either Human Colorectal Fibroblast Cells (Co-18) or Lung Fibroblast Cells (IMR-91).*
32. **Poster Discussion Presentation** at the **41st Annual Meeting of the American Society of Clinical Oncology**, May 13 – 17, 2005, Orlando, Florida. **P. Kumar**, et al. *Mature Results of Radiation Therapy Oncology Group (RTOG) Trial 9615 Using Intra-Arterial Cisplatin and Concurrent Radiation Therapy for Stage IV-T4 Head and Neck Squamous Cell Carcinoma.*
33. **Poster Discussion Presentation** at the **Radiological Society of North America 92nd Scientific Assembly and Annual Meeting**, November 26 – December 1, 2006, Chicago, Illinois. **P. Kumar**, et.al. *Treatment of Lung Lesions with Cyberknife Stereotactic Radiotherapy: Initial Experience at the University of Southern California.*

H. INVITED SPEAKERSHIP (continued):

Presentations at Major National and International Meetings (as Presenter and / or First Author -- continued):

34. **Poster Discussion Presentation** at the **Radiological Society of North America 93rd Scientific Assembly and Annual Meeting**, November 25 – 30, 2007, Chicago, Illinois. **P. Kumar**, et.al. *Treatment of Lung Lesions is Safe and Effective with Cyberknife Stereotactic Radiotherapy: Initial Experience at the University of Southern California.*
35. **Poster Presentation** at the **90th American Radium Society (ARS) 2008 Annual Meeting**, Dana Point, California, May 3 – 7, 2008. **P. Kumar** et.al. *Safety and Efficacy of Cyberknife Treatment for Lung Lesions: The University of Southern California Experience.*
36. **Poster Presentation** at the **American Society for Radiation Oncology (ASTRO) 54th Annual Meeting**, Boston, Massachusetts, October 28 – 31, 2012. **Parvesh Kumar, M.D.** *Four-Dimensional Cone Beam CT (4D-CBCT) Significantly Improves Localization of Lung Tumors in Comparison to ExacTrac X-Ray 6D Image Guidance (ExacTrac) in the Delivery of Stereotactic Body Radiotherapy (SBRT).*
37. **Poster Presentation** at the **55th Annual American Society of Therapeutic Radiation Oncology Meeting**, Atlanta, GA, September 22 – 25, 2013. **P. Kumar**, P. Veldhuizen, M. Thompson, X. Shen, J. Pinski. *Preliminary Results of an On-Going Phase I/II Trial of Tri-Modality Therapy using Hormonal Therapy, Radiation Therapy (RT) and concurrent Docetaxel in Patients with High Risk Pathologic T2-3N0M0 Prostate Cancer.*
38. **Poster Presentation** at the **American Radium Society's 96th Annual Meeting**, St. Thomas, U.S. Virgin Islands, April 26 – 29, 2014. **P. Kumar**, P. Veldhuizen, M. Thompson, X. Shen, J. Coster, J. Pinski. *Feasibility and Efficacy of Tri-Modality Therapy in Patients with High Risk Pathologic T2-3N0M0 Prostate Cancer: Preliminary Results of an On-Going Phase I-II Trial.*
39. **Poster Presentation** at the **56th Annual American Society of Therapeutic Radiation Oncology Meeting**, San Francisco, CA, September 14 – 18, 2014. **P Kumar**, et. al. *Recently Updated Preliminary Results of an On-Going Phase I/II Trial Using Tri-modality Therapy in Patients with Post-Prostatectomy High Risk Pathologic (p) T2-3N0M0 Prostate Cancer.*

H. INVITED SPEAKERSHIP (continued):

Presentations at Major National and International Meetings (as Presenter and / or First Author -- continued):

40. **Poster Presentation at the 57th Annual American Society of Therapeutic Radiation Oncology Meeting**, San Antonio, TX, October 18 -21, 2015. **P. Kumar**, P. V. Veldhuizen, M. Thompson, X. **Shen**, J. Coster, J. Pinski. *Preliminary Results of a Nearly Completed Phase I-II Trial Using Trimodality Therapy In Patients With Post Prostatectomy High Risk Pathologic (p) T2-3N0M0 Prostate Cancer.*
41. **ePoster Discussion at the 58th Annual American Society for Therapeutic Radiation Oncology Meeting**, Boston, MA, September 25 – 28, 2016. **P.Kumar**, P. Veldhuizen, M. Thompson, X. Shen, and J. Pinski. *Trimodality Therapy Is Tolerable and Feasible in Patients With Postprostatectomy High-Risk Pathology (p) T2-3N0M0 Prostate Cancer: Results of a Phase I-II Trial.*
42. **Poster Presentation at the 100th Annual American Radium Society Meeting**, Orlando, FL, May 5-8, 2018. **P. Kumar**, C. Cross, S. Moonie, J. and De Leon. *Rural-Urban Continuum as a Potential Geographic Correlate of Breast and Prostate Cancer Mortality in Nevada.*
43. **Poster Presentation at the 60th Annual Meeting for the American Society for Therapeutic Radiation Oncology (ASTRO)**, San Antonio, TX, October 21 – 24, 2018. **P. Kumar**, C. Cross, J. De Leon, and S. Moonie. *Impact of Mammography Screening Rates on Breast Cancer Mortality (NV), California (CA) and US: Implications for Health Care Policy.*
44. **Poster Presentation at the 2019 NIH IDeA Western Regional Conference**, October 7-9, 2019, Las Vegas, **Kumar, P.** *The MW CTR-IN Program.*
45. **Poster Presentation at the 2019 Radiological Society of North America (RSNA)**, December 1, 2019, Chicago, IL, C Cross, PhD; **P. Kumar**, MD, Las Vegas, NV; K Gutierrez, BS; S Moonie, PhD *The Impact of Sociodemographic Factors in Breast, Prostate and Lung Cancer in the Patterns of Care Related to the Availability of Radiation Therapy (RT) in a Rural Mountain West State*

I. SCHOLARLY PUBLICATIONS

Book Chapters:

1. **Kumar P.** Is Radiation Therapy the Standard of Care for Advanced Oropharyngeal Squamous Cell Carcinoma? *Head and Neck Cancer: Organ Preservation, Function and Rehabilitation.* Editors: K. Thomas Robbins and Thomas Murry, Chapter 16, pp. 97-104, 1998.

I. SCHOLARLY PUBLICATIONS (continued)

Book Chapters (continued):

2. **Kumar P.** The Role of Thoracic Radiation Therapy and Prophylactic Cranial Irradiation in the Management of Small Cell Lung Cancer: Where Have We Been, Where Are We Now, and Where Do We Need To Go? Multimodality Therapy of Lung Cancer: Lung Biology in Health and Disease. Editor: A. Skarin, Chapter 16, pp.351-380, 1999. Sponsored as a continuing series by the National Institute of Health.
3. **Kumar P.** Three Dimensional Conformal Radiation Therapy: Practical Aspects, Therapeutic Ratio, and Future Directions. *Management of Prostate Cancer: Advances & Controversies*. Editor: Kenneth B. Cummings, M.D., Chapter V, pp. 171-203, 2004.
4. **Kumar P.** Radiation Therapy for the Larynx and Hypopharynx. In Cummings CW et al: Otolaryngology-Head and Neck Surgery, 4th edition. Philadelphia, Elsevier. Volume 3, Chapter 104, pp. 2401-2419, 2005.
5. **Kumar P.** Textbook of Uncommon Cancer, 3rd edition, England, Wiley. *Uncommon Cancers of the Prostate*. Editors: Derek Raghavan, Martin L. Brecher, David H. Johnson, Neal J. Meropol, Paul L. Moots, Peter G. Rose, Ingrid A. Mayer. Chapter 1, pp. 38-65, 2006.
6. Cheuk A., **Kumar P.** Radiation Therapy for the Larynx and Hypopharynx. In Cummings CW et al: Otolaryngology-Head and Neck Surgery, 5th edition. Philadelphia, Elsevier, Volume 2, Chapter 112, pp. 1577-1593, 2010.
7. Lominska, C., **Kumar, P.** Radiation Therapy for the Larynx and Hypopharynx. In Cummings CW et al: Otolaryngology-Head and Neck Surgery, 6th edition. Philadelphia, Elsevier-Saunders Inc., Volume II, Chapter 111, pp. 1714-1731, 2015.
8. **Kumar, P.** Radiation Therapy for the Larynx and Hypopharynx. In Cummings CW et al: Otolaryngology-Head and Neck Surgery, 7th edition. Philadelphia, Elsevier-Saunders Inc., Volume II, Chapter 110, pp. 1677-1695, 2020.

Published / Presented Abstracts:

1. **Kumar P,** Kun LE, Hustu HO, Hancock ML, Rivera GK. *Factors Associated with Outcome Following Isolated Meningeal Relapse Treated with Craniospinal Irradiation in Childhood Acute Lymphoblastic Leukemia.* Oral presentation at the 33rd Annual American Society for Therapeutic Radiology and Oncology Meeting, Washington, DC, November 4 – 8, 1991, *Int J Radiat Oncol Biol Phys* 21(S1):168, 1991.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

2. **Kumar P**, Kun LE, Rivera GK, Mulhern RK. *A Prospective Neuropsychological Evaluation of Children Treated with Additional Chemotherapy and Craniospinal Irradiation (CSI) Following Central Nervous System (CNS) Relapse in Acute Lymphoblastic (ALL)*. Oral presentation at the 35th Annual American Society for Therapeutic Radiology and Oncology Meeting, New Orleans, Louisiana, October 11 – 15, 1993, *Int J Radiat Oncol Biol Phys* 27(1):134, 1993.
3. Regine WF, Greenwald C, **Kumar P**, Dombrowski J, Ballas D, Pappo A, Shapiro D, Bowman L, Rao B, Kun LE. *Use of Altered Radiation (RT) Dose and Fractionation in Patients with Unresectable Rhabdomyosarcoma (RMS) Based Upon Disease Status Following Induction Therapy: The St. Jude Experience*. Oral presentation at the 30th Annual Meeting of the American Society of Clinical Oncology in Dallas, Texas, May 14 – 17, 1994. *Proceedings of the American Society of Clinical Oncology*, 13:419 (#1433), March 1994.
4. Sugarbaker D, Herndon J, Kohman L, Shennib H, Nugent W, Krasna M, Olak J, Dresler C, Ferguson M, Reed C, Kass F, **Kumar P**, Jaklitsch M, Maddaus M, Altorki N, Green M. *Patterns of Recurrence in CALGB 8935, a Tri-Modality Trial for IIIA (N₂) Non-Small Cell Lung Cancer (NSCLC)*. Poster presentation at the 30th Annual Meeting of the American Society of Clinical Oncology in Dallas, Texas, May 14-17, 1994. *Proceedings of the American Society of Clinical Oncology*, 13:348 (#1165), 1994.
5. Sugarbaker D, Herndon II J, Kohman L, Shennib H, Nugent W, Krasna M, Olak J, Dresler C, Ferguson M, Reed C, Kass F, **Kumar P**, Jaklitsch M, Maddaus M, Altorki N, Green M. *Results of CALGB 8935: A Multi-Institutional Phase II Tri-Modality Trial for Stage IIIA (N₂) Non-Small Cell Lung Cancer (NSCLC)*. Oral presentation at 74th Annual American Association of Thoracic Surgery Meeting, New York, New York, April 24 – 27, 1994. *Program of Annual Meeting*, 52:166-167, 1994.
6. Robbins KT, Vicario D, Murry T, Weisman RA, Gold SE, Seagren SL, **Kumar P**, Howell SB. *A Novel Organ Preservation Treatment Protocol for Advanced Head and Neck Cancer*. Oral presentation at the 1994 Annual Meeting of the American Academy of Otolaryngology - Head and Neck Surgery Foundation, San Diego, California, September 1994.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

7. **Kumar P**, Sugarbaker D, Herndon II J, Langer M, Elias AD, Kohman L, Jaklitsch M, Kass FC, Eaton WL, Seagren S, Green M. *Efficacy and Safety of Tri-Modality Treatment in Patients with Pathologically Staged IIIA (N₂) Non-Small Cell Lung Cancer (NSCLC) Utilizing Consolidative Thoracic Irradiation: Results of Cancer and Leukemia Group B (CALGB) Trial 8935*. Oral presentation at the 36th Annual American Society for Therapeutic Radiology and Oncology Meeting, San Francisco, California, October 1994, *Int J Radiat Oncol Biol Phys* 30(S1):180, 1994.
8. Griffin JP, **Kumar P**, Miller AA, Burch MA, Niell HB. Lung Cancer: *Efficacy of Radiation/Chemotherapy*. Poster presentation at the 61st Annual International Scientific Assembly of American College of Chest Physicians in New York, New York, October 29 – November 2, 1995. *Chest*, 108(3):201S, September 1995.
9. **Kumar P**, Herndon II J, Langer M, Liptay MJ, Sugarbaker DJ, Kohman LJ, Shennib H, **Kumar P**, Mulhern RK, Rivera GK, Kun LE. *Gender Based Differences in Neurocognitive Outcome Following Treatment of Isolated Central Nervous System (CNS) Relapse with Additional Chemotherapy (CT) and Craniospinal Irradiation (CSI) in Acute Lymphoblastic Leukemia (ALL)*. Oral presentation at the *Evolving Role of Radiation Therapy in Pediatric Oncology Meeting*, sponsored by the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, January 19 – 21, 1995.
10. **Kumar P**, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR. *Patterns of Relapse Following Tri-Modality Treatment in Patients with Pathologically Staged IIIA (N₂) Non-Small Cell Lung Cancer (NSCLC): Analysis of Cancer and Leukemia Group B (CALGB) Protocol 8935*. Oral presentation at the American Radium Society Meeting in Paris, France, April 29 – May 3, 1995. *Proceedings of the American Radium Society 78th Annual Meeting*, 63:31, 1995.
11. **Kumar P**, Rivera WF, Hancock ML, Mulhern RK, Kun LE. *Long Term Survival and Neurocognitive Outcome Following Isolated Central Nervous System (CNS) Relapse in Childhood Acute Lymphoblastic Leukemia (ALL)*. Oral presentation at the 31st ASCO Meeting, Los Angeles, California, May 20 – 23, 1995. *Proceedings of the American Society of Clinical Oncology*, 14:343 (#1033), 1995.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

12. **Kumar P**, Regine WF, Kun LE, Hanchett C. , Palmer R, Fontanesi J, Paig CU, Harrington V, Flick PA, Ferguson R, Murry T, Wong FS, Niell HB, Weir III A, Robbins KT. *Efficacy of Supradose Intra-Arterial Targeted (SIT) Cisplatin (P) and Concurrent Radiation Therapy (RT) in the Treatment of Unresectable Stage III-IV Head and Neck (H/N) Carcinoma.* Oral presentation at the 37th Annual American Society for Therapeutic Radiology and Oncology Meeting, Miami Beach, Florida, October 8 – 11, 1995. *Int J Radiat Oncol Biol Phys* 32(S1):193 (#105), 1995.
13. **Kumar P**, Kun LE, Flick PA, Wong FS, Murry T, Robbins KT. *Treatment of Unresectable Stage III-IV Head and Neck (N/N) Carcinoma Using Intra-Arterial Targeted (SIT) Cisplatin (P) and Concurrent Radiation Therapy (RT).* Poster presentation at the 8th European Cancer Conference in Paris, France, October 29 – November 2, 1995. *European Journal of Cancer* 31A (S5):S89, 1995.
14. Robbins KT, **Kumar P**, Weisman R, Wong FS, Hartsell W, Niell HB, Howell S. *Outcome Analysis of Head and Neck Cancer Patients Treated with a Novel Targeted Chemoradiation Protocol.* Oral presentation at the American Laryngological, Rhinological and Otological Society, Inc. (Triological Society), May 5 – 8, 1996, Orlando, Florida.
15. Aggarwal R, Yeung D, Muhlbauer M, **Kumar P**, Kun LE. *Efficacy and Feasibility of Stereotactic Radiosurgery in the Primary Management of Unfavorable Pediatric Ependymoma: A Phase II Pilot Study.* Oral presentation at the “LINAC Radiosurgery 1995 Meeting,” (sponsored by the Department of Neurosurgery and Radiation Oncology at the University of Florida, Gainesville), December 6 – 10, 1995, Lake Buena Vista, Florida.
16. Samant S, **Kumar P**, Vieira F, Hanchett C, Murry T, Hartsell W, Palmer R, Gonzalez D, Wong FSH, Robbins KT. *Concomitant Radiation and Targeted Supradose Cisplatin Chemotherapy for Piriform Sinus Cancer: Disease Control and Organ-Function Preservation.* Oral presentation at the Fourth International Conference on Head and Neck Cancer, July 28 – August 1, 1996, Toronto, Canada. *Proceedings of the 4th International Conference on Head and Neck Cancer, p. 101 (#172), 1996.*

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

17. Robbins KT, **Kumar P**, Weisman RA, Wong FSH, Hartsell W, Weir III AB, Niell B, Los G, Christen R, Palmer R, Seagren SL, Ferguson R, Flick PA, Kerber CW, Howell SB. *Phase II Trial of Targeted Supradose Cisplatin (DDP) and Concomitant Radiation Therapy (RT) for Patients with Stage III-IV Head and Neck Cancer*. Oral presentation at the Fourth International Conference on Head and Neck Cancer, July 28 – August 1, 1996, Toronto, Canada. *Proceedings of the 4th International Conference on Head and Neck Cancer, p. 132 (#293), 1996.*
18. **Kumar P**, Wan J, Paig CU, Kun LE, Niell HB. *Feasibility of Accelerated Radiotherapy (AR) Using a Concomitant Boost for the Treatment of Unresectable Non-Small Cell Lung Cancer (NSCLC): A Phase II Study*. Poster presentation at the 38th Annual American Society for Therapeutic Radiology and Oncology Meeting, Los Angeles, California, October 27 – 30, 1996. *Int J Radiat Oncol Biol Phys 36(S1):347 (#2143), 1996.*
19. **Kumar P**, Herndon J II, Glicksman A, Eaton W, Langer M, Kass FC, Seagren S, Green M, Sugarbaker DJ. *Does the Quality of Radiation Therapy (RT) Impact Upon Outcome in the Tri-Modality Treatment of Stage IIIA (N₂) Non-Small Cell Lung Cancer (NSCLC): Analysis of Cancer and Leukemia Group B (CALGB) Protocol 8935*. Poster presentation at the 38th Annual American Society for Therapeutic Radiology and Oncology Meeting, Los Angeles, California, October 27 – 30, 1996. *Int J Radiat Oncol Biol Phys 36(S1):344 (#2135), 1996.*
20. **Kumar P**, Wan J, Paig CU, Kun LE, Niell HB. *Feasibility of Accelerated Radiotherapy (AR) Using a Concomitant Boost in the Treatment of Unresectable Non-Small Cell Lung Cancer (NSCLC): A Phase II Study*. Poster presentation at the 15th Annual European Society for Therapeutic Radiology and Oncology Meeting, Vienna, Austria, September 23 – 26, 1996. *Radiotherapy and Oncology 40(S1):S153, 1996.*
21. **Kumar P**, Wan J, Regine WF, Vieira F, Wong FSH, Robbins KT. *Analysis of Prognostic Factors (PF) in the Treatment of Unresectable Stage III-IV Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Using Supradose Intra-Arterial Targeted Cisplatin (SIT-P) and Concurrent Radiation Therapy (RT)*. Poster presentation at the 15th Annual European Society for Therapeutic Radiology and Oncology Meeting, Vienna, Austria, September 23 – 26, 1996. *Radiotherapy and Oncology 40(S1): S98, 1996.*

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

22. Hartsell W, Clark C, Fontanesi J, Desai G, Shah A, **Kumar P**, Tai D, Kun LE. *Interstitial I-125 Implantation of Malignant Gliomas*. Oral presentation at the 15th Annual European Society for Therapeutic Radiology and Oncology Meeting, Vienna, Austria, September 23 – 26, 1996. *Radiotherapy and Oncology* 40(S1):S82, 1996.
23. LE Kun, **P Kumar**, D Jones, J Fontanesi, EC Douglass, R Ribeiro. *Long Term Outcome Following Curative Therapy of Pediatric Nasopharyngeal Carcinoma (PNC): Three Decade Experience at St. Jude Children's Research Hospital (SJCRH)*. Oral presentation at the 33rd Annual ASCO Meeting, Denver, Colorado. *Program/Proceedings of the American Society of Clinical Oncology*, 16:512a (#1841), 1997.
24. **P Kumar**, J Wan, F Vieira, FSH Wong, W Hartsell, G Desai, HB Niell, KT Robbins. *Analysis of Survival Outcome and Prognostic Factors (PF) in the Treatment of Unresectable Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Using Supradose Intra-Arterial Targeted Cisplatin (SIT-P) and Concurrent Radiation Therapy (RT)*. Poster discussion presentation at the 33rd Annual American Society of Clinical Oncology Meeting, Denver, Colorado. *Program/Proceedings of the American Society of Clinical Oncology*, 16:390a (#1394), 1997.
25. HB Niell, AA Miller, **P Kumar**, JP Griffin. *Phase I/II Trial of Paclitaxel (TAX), Cisplatin (DDP) and Radiation Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)*. Poster discussion presentation at the 33rd Annual American Society of Clinical Oncology Meeting, Denver, Colorado. *Program/Proceedings of the American Society of Clinical Oncology*, 16:447a (#1606), 1997.
26. Elias AD, Herndon J, **Kumar P**, Sugarbaker D, Green MR. *A Phase III Comparison of "Best Local-Regional Therapy" With or Without Chemotherapy (CT) for Stage IIIA T1-3, N2 Non-Small Cell Lung Cancer (NSCLC): Preliminary Results*. Poster discussion presentation at the 33rd Annual ASCO Meeting, Denver, Colorado. *Program/Proceedings of the American Society of Clinical Oncology*, 16:448a (#1611), 1997.
27. **P Kumar**, J Herndon II, DJ Sugarbaker, MR Green for CALGB. *Impact of Initial Hemoglobin Levels Upon Survival Outcome Following Trimodality Treatment of Surgically Staged IIIA (N2) Non-Small Cell Lung Cancer (NSCLC): Updated Analysis of Cancer and Leukemia Group B (CALGB) Protocol 8935*. Poster presentation at the 8th IASLC Conference, Dublin, Ireland. *Lung Cancer*, 18(S1):71 (#271), 1997.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

28. **P. Kumar**, J. Herndon II, AD Elias, DJ Sugarbaker, MR Green for CALGB. *Comparison of Pre-Operative Thoracic Radiation Therapy (TRT) to Pre-Operative Chemotherapy (CT in Surgically Staged IIIA (N₂) Non-Small Cell Lung Cancer (NSCLC): Initial Results of Cancer and Leukemia Group B (CALGB) Phase III Protocol 9134.* Oral presentation at the 39th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, October 19 – 22, 1997, Orlando, Florida. Int J. Radiat Oncol Biol Phys 39(S2):195 (#121) 1997.
29. LA Newman, S French, F Vieira, **P Kumar**, KT Robbins. *Peg Tube Placement, Weight Loss and Side Effects During Intra-Arterial Chemo-Radiation.* Presented at the Sixth Annual Scientific Meeting of the Dysphagia Research Society, October 16 – 18, 1997, Toronto, Ontario, Canada.
30. J Watson, C Hanchett, **P Kumar**, KT Robbins. *Co-morbidity and Survival in Chemoradiation for Advanced Head and Neck Cancer.* Presented at The American Laryngological, Rhinological and Otological Society Meeting, January 5, 1998, Orlando, Florida.
31. **P Kumar**, J Wan, F Vieira, FSH Wong, HB Niell, KT Robbins. *Long Term Outcome in the Treatment of Stage III-IV Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Using Supradose Intra-Arterial Targeted Cisplatin (SIT-P) and Radiation Therapy (RT).* Poster presentation at the 34th Annual American Society Clinical Oncologists Meeting, May 16 – 19, 1998, Los Angeles, California. Program / Proceedings of the American Society of Clinical Oncology, 17:381a (#1469), 1998.
32. DJ Sugarbaker, J. Herndon, MM Decamp, MT Jaklitsch, WG Richards, **P Kumar**, MR Green. *N₂ Status at Resection Predicts Long-Term Outcome Following Induction Therapy for Stage IIIA Non-Small Cell Lung Cancer: CALGB 8935.* Poster presentation at the 34th Annual ASCO Meeting, May 16 – 19, 1998, Los Angeles, California. Program/Proceedings of the American Society of Clinical Oncology, 17:452a (#1739), 1998.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

33. **P Kumar**, J Wan, E Proctor, F Vierra, RE Palmer, FSH Wong, KT Robbins. *The Impact of Radiation Related Factors Upon Long Term Outcome in the Management of Advanced Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Treated With Supradose Intra-Arterial Targeted (SIT) Cisplatin (P) and Radiation Therapy (RT).* Poster presentation at the 40th Annual American Society for Therapeutic Radiology and Oncology Meeting, October 25 – 29, 1998, Phoenix, Arizona. *Int J Radiat Oncol Biol Phys* 42(S1):321 (#2188), 1998.
34. **P Kumar**, J Wan, F Vieira, FSH Wong, KT Robbins. *Five Year Outcome Analyses Following Treatment of Stage III/IV Head and Neck (H/N) Squamous Cell Carcinoma (SCCa) Using Supradose Intra-Arterial Targeted Cisplatin (SIT-P) and Concurrent Radiation Therapy (RT).* Poster presentation at the 35th Annual American Society of Clinical Oncology Meeting, May 15 – 18, 1999, Atlanta, Georgia. *Program/Proceedings of the American Society of Clinical Oncology*, 18:396a (#1530), 1999.
35. **P Kumar**, J Wan, E Proctor, F Vierra, RE Palmer, FSH Wong, KT Robbins. *The Prophylactic Use of Pentoxifylline in the Therapy of Stage IV-N_{2,3} Head & Neck (H/N) Squamous Cell Carcinoma (SCCa) Treated with Supradose Intra-arterial Targeted Cisplatin (SIT-P) and Concurrent Radiation Therapy (RT): Preliminary Results of a Pilot Study.* Poster discussion presentation at the 41st Annual American Society for Therapeutic Radiology and Oncology Meeting, October 31 – November 4, 1999, San Antonio, Texas. *Int J Radiat Oncol Biol Phys*, 45(3S):279, 1999.
36. Shannon KF, Robertson JT, **Kumar P**, Robbins KT. *Intra-arterial cisplatin and concurrent radiotherapy in the treatment of paranasal sinus cancer. *Skull Base Surg.* 1999, 9:28.*
37. **P Kumar**, J Herndon, II, DJ Sugarbaker, L Kohman, AD Elias, MR Green. *Long Term Survival Outcome of a Sequential Trimodality Trial in Pathologically Staged IIIA (N2) Non-Small Cell Lung Cancer (NSCLC): Final Results of Cancer and Leukemia Group B Protocol (CALGB) Protocol 8935.* Poster presentation at the 36th Annual Meeting of the American Society of Clinical Oncology, *Program/Proceedings of the American Society of Clinical Oncology*, 19:496a (#1939), 2000. May 20 – 23, 2000, New Orleans, Louisiana.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

38. KT Robbins, J Harris, **P Kumar**, P Levine, T McCulloch, R Sofferman, R Christien. *Targeted Chemoradiation (RADPLAT) for T4 Carcinoma of the Upper Aerodigestive Tract (RTOG 96-15): Interim Analysis of a Multi-Institutional Trial*. Oral presentation at the 5th International Conference on Head and Neck Cancer, July 29 – August 2, 2000, San Francisco, California. Proceedings of the 5th International Conference on Head and Neck Cancer, p. 78 (#46), 2000.
39. **P Kumar**, F Vierra, FSH Wong, KT Robbins. *Pre-Treatment Hemoglobin (HGB) Level is a Significant Predictor of Response Rates (RR) and Survival in State III/IV Head and Neck (H/N) Squamous Cell Carcinoma (SCCA) Treated with Intra-Arterial (IA) Cisplatin and Radiation Therapy (RT)*. Oral presentation at the 5th International Conference on Head and Neck Cancer, July 29 – August 2, 2000, San Francisco, California. Proceedings of the 5th International Conference on Head and Neck Cancer, p. 154 (#351), 2000.
40. **P Kumar**, J Harris, KT Robbins, P Levine, T McCulloch, R Sofferman. *The Feasibility of Using Intra-Arterial Cisplatin & Radiation Therapy for State IV-T4 Head/Neck (H/N) Squamous Cell Carcinoma in a Multi-Institutional Setting: Preliminary Results of Radiation Therapy Oncology Group (RTOG) Trial 9615*. Oral presentation at the American Society of Therapeutic Radiology and Oncology 42nd Annual Meeting. Int J Radiat Oncol Biol Phys 48(3):152(#81), October 22 – 26, 2000, Boston, Massachusetts.
41. **P Kumar**, M Perrotti, R Weiss, M Todd, K Cummings, R DiPaola. *A Novel Therapeutic Strategy Testing the Safety and Feasibility of Concurrent Docetaxel and 3-D Conformal Radiation Therapy (RT) in Patients with High Risk Localized Adenocarcinoma of the Prostate: Progress Report of an On-Going Phase I Trial*. Poster presentation at the 38th Annual Meeting of the American Society of Clinical Oncology, Proceedings of the American Society of Clinical Oncology, 21:194a (#772), 2002. May 18 – 21, 2002, Orlando, Florida.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

42. **P Kumar**, R Weiss, M Todd, K Cummings, R DiPaola. *The Safety and Feasibility of Concurrent Docetaxel and 3-D Conformal Radiation Therapy (3-D CRT) In Patients with High Risk Localized Adenocarcinoma of the Prostate: Preliminary Report of an On-Going Phase I Trial.* Poster presentation at the 44th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, *Int J Radiat Oncol Biol Phys* 54(2):191-192(#1057), October 6 – 10, 2002, New Orleans, Louisiana.
43. **P Kumar**, M Perrotti, R Weiss, K Cummings, M Todd, S Goodin, R DiPaola. *The Safety of Concurrent Docetaxel and 3-D Conformal Radiation Therapy (CRT) In Patients with High Risk Localized Adenocarcinoma of the Prostate: Results of a Completed Phase I Trial.* Poster presentation at the 39th Annual Meeting of the American Society of Clinical Oncology, Proceedings of the American Society of Clinical Oncology, 22:404(#1622), 2003. May 31 – June 3, 2003, Chicago, Illinois.
44. **P Kumar**, M Mehta, P Rodrigus, J Suh, S Sagar, I Kunkler, C Carrie, JA Smith, SC Phan, MF Renschler. *Motexafin Gadolinium (MGd) Overcomes Adverse Survival Effect of Anemia in Brain Metastases (BM) Patients Treated with Whole Brain Radiation Therapy (WBRT): Analysis of a Phase III Randomized Trial.* Oral presentation at the 45th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, *Int J Radiat Oncol Biol Phys* 57(2):S133(#16). October 19 – 23, 2003, Salt Lake City, Utah.
45. **P Kumar**, J Harris, AS Garden, K Fu, KT Robbins, T Pajak, KK Ang. *Outcome Comparisons of Four Radiation Therapy Oncology Group (RTOG) Trials in Patients with Stage IV-T4 Head and Neck Cancer: Encouraging Results Using Intra-Arterial (IA) Cisplatin (P) and Concurrent Radiation Therapy (RT).* Poster discussion presentation at the 40th Annual Meeting of the American Society of Clinical Oncology, Annual Meeting Proceedings of the American Society of Clinical Oncology, 23:493 (#5527), 2004. June 5 – 8, 2004, New Orleans, Louisiana.
46. **P Kumar**, J Harris, AS Garden, K Fu, KT Robbins, T Pajak, KK Ang. *Comparison of Intra-Arterial Cisplatin and Radiation Therapy (RT) to Other Radiation Therapy Oncology Group (RTOG) Regimens Using Standard or Accelerated RT With or Without Concurrent Chemotherapy in Patients with Stage IV-T4 Head and Neck Cancer.* Poster presentation at the 46th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, *Int. J. Radiation Oncol. Biol. Phys.* 60(1):S495-496(#2266). October 3 – 7, 2004, Atlanta, Georgia.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

47. **P Kumar**, CK Hill. *In Vitro Biological Effects of 13-Cis-Retinoic Acid (CRA) & Interferon-Alpha (IFN) combination with or without Radiation more selectively Down Regulates BCL-2 and Increases Apoptosis in Prostate Tumor Cells (LnCAP) than in either Human Colorectal Fibroblast Cells (Co-18) or Lung Fibroblast Cells (IMR-91)*. Proceedings of the European Society for Therapeutic Radiology Oncology (ESTRO) 23 #876, pg. S373, 2004, October 24 – 29, 2004, Amsterdam, Netherlands.
48. M Maish, **P Kumar**, J Hagen. *Initial Thoracic Experience in the Treatment of Lung Lesions with the Cyberknife Stereotactic Radiosurgery System at the University of Southern California*. Proceedings of the European Society for Therapeutic Radiology Oncology (ESTRO) 23 #1030, pg. S433, 2004, October 24 – 29, 2004, Amsterdam, Netherlands.
49. Colin K. Hill, **Parvesh Kumar**. *In Vitro effects of 13-cis retinoic acid (CRA) and Interferon Alpha (IFN) with or without radiation (XRT) on prostate tumor cells (LNCAP), normal human rectal cells (CO-18) and normal human lung fibroblast (IMR-91) cells*. Proceedings of the 96th Annual Meeting of the American Association of Cancer Research, Anaheim, California, April 16 – 20, 2005.
50. **P Kumar**, K.T. Robbins, J. Harris, T. McCulloch, A. Cmelak, R. Sofferman, P. Levine, K. Fu. *Mature results of Radiation Therapy Oncology Group (RTOG) Trial 9615 using intra-arterial cisplatin (IA-P) and concurrent radiation therapy (RT) for stageIV-T4 head/neck (H/N) squamous cell carcinoma (SCCa)*. Poster discussion presentation at the 41st Annual Meeting of the American Society of Clinical Oncology, Journal of Clinical Oncology, 23:16S (#5579), 2005. May 13 – 17, 2005, Orlando, Florida.
51. **P. Kumar**, O. Streeter, Jr., J. Hagen. *Treatment of Lung Lesions is safe and effective with Cyberknife Stereotactic Radiotherapy: The Thoracic experience at the University of Southern California*. Radiotherapy & Oncology 2006; 81:1S (#S493).
52. **P. Kumar**, J. Huang, M. Astrahan, A. Cheuk, O. Streeter, Jr., J. Hagen. *Treatment of Lung Lesions with Cyberknife Stereotactic Radiotherapy: Initial Experience at the University of Southern California*. Poster discussion presentation, Proceedings of the Radiological Society of North America 92nd Scientific Assembly and Annual Meeting, p. 479, 2006, November 26 – December 1, 2006.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

53. Colin K. Hill, **Parvesh Kumar**, Grant Dagliyan. *Potential role for 13-cis-retinoic acid and alpha interferon to increase radiation effectiveness via abrogation of bcl-2 over expression in prostate tumor cells while sparing normal colonic cells.* Poster Presentation, at the 13th International Congress of Radiation Research (ICCR), 2007 International Congress of Radiation Research Abstract Book, pp. 109-110, San Francisco, California, July 8 – 12, 2007.
54. **P. Kumar**, J. Huang, M. Astrahan, A. Cheuk, O. Streeter, Jr., J. Hagen. *Treatment of Lung Lesions is Safe and Effective with Cyberknife Stereotactic Radiotherapy: Initial Experience at the University of Southern California.* Poster discussion presentation at the Radiological Society of North America (RSNA) 93rd Scientific Assembly and Annual Meeting, Chicago, Illinois, November 25 – 30, 2007.
55. **Parvesh Kumar**, Alice V. Cheuk, Melvin A. Astrahan, Thomas D. Kampp, Oscar E. Streeter, Jr., Jeffrey A. Hagen. *Safety and Efficacy of Cyberknife Treatment for Lung Lesions: The University of Southern California Experience,* Poster Presentation (P72), Proceedings of the 90th American Radium Society (ARS) 2008 Annual Meeting, p.54, Dana Point, California, May 3 – 7, 2008.
56. S. Harirchian, **P. Kumar**, B. Gitlitz, U.K. Sinha, *Management of Recurrent Squamous Cell Carcinoma in the Infratemporal Fossa,* Poster Presentation (P190), Proceedings of the 7th International Conference on Head and Neck Cancer, p.262, San Francisco, California, July 19 – 23, 2008.
57. Michael S. Eaton, Michele Kovas, Uttam Sinha, **Parvesh Kumar.** *Comprehensive Hyperfractionated (HFx) Re-Irradiation (Re-RT) of Recurrent Head and Neck (H/N) Cancer is Feasible: A Retrospective Review of the University of Southern California Experience.* Oral Presentation (RO-22-03), Scientific Assembly and Annual Meeting Program of the Radiological Society of North America (RSNA) 94th Scientific Assembly and Annual Meeting, p. 165, Chicago, Illinois, November 30 – December 5, 2008.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

58. Alice V. Cheuk, **Parvesh Kumar**, Melvin A. Astrahan, Thomas D. Kampp, Oscar Streeter, Jr., Jeffrey A. Hagen. *Cyberknife (CK) Stereotactic Radiotherapy (SRT) for Primary and Metastatic Lung Lesions is Safe and Efficacious*. Poster Presentation (P091), at the American Radium Society (ARS) 91st International Meeting, Oncology, 23:4, Supplement # 2 (p.55). April 25 – 29, 2009. Vancouver, British Columbia, Canada.
59. B. Aika Shoo M.D., Afshin Rashtian, M.D., Dennis R. Holmes, M.D., **Parvesh Kumar, M.D.**, Oscar E. Streeter Jr., M.D. *Feasibility, Toxicity and Outcome for MammoSite Intracavitary Brachytherapy for Early Stage Breast Cancer: Preliminary Results from a Single Institution* Poster Presentation, at the Los Angeles Radiological Society (LARS) / Southern California Radiation Oncology Society (SCROS) 62nd Annual Midwinter Radiology & Radiation Oncology Conference, Program/Proceedings p. 822. January 30 – 31, 2010, Pasadena Convention Center, Pasadena, California.
60. Michael S. Eaton, M.D., Ph.D., Michele Kovas, Uttam Sinha, M.D., **Parvesh Kumar, M.D.** *Comprehensive Hyperfractionated (HFx) Re-Irradiation (Re-RT) of Recurrent Head and Neck (H/N) Cancer is Feasible: A Retrospective Review of the University of Southern California Experience*. Poster Presentation (P070), at the 92nd American Radium Society (ARS) 2010 International Meeting, Meeting Proceedings, p. 61-62, Cancun, Mexico, May 1 – 5, 2010.
61. Uttam Sinha, M.D., **Parvesh Kumar, M.D.** *Comprehensive Volume Hyperfractionated (HFx) Re-Irradiation (Re-RT) of Recurrent Head and Neck (H/N) Cancer is Feasible*. Poster Presentation at the **American Society of Clinical Oncology (ASCO) 2011 Annual Meeting**, Chicago, Illinois, June 3 – 7, 2011. J Clin Oncol 29: 2011 (suppl; abstr 5551)
62. F. Wang, S. Das, J. Park, R. Badkul, S. Hus, **P. Kumar**. *Validation and Reliability of Free Breathing Cone Beam Computed Tomography (FB-CBCT) Imaging Guidance in Stereotactic Ablative Radiotherapy (SABR) of Lung Tumors*. Poster Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, Illinois, September 6 – 8, 2012.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

63. **P. Kumar**, S. Das, J. Park, R. Badkul, S. Hus, F. Wang. *Four-Dimensional Cone Beam CT (4D-CBCT) Significantly Improves Localization of Lung Tumors in Comparison to ExacTrac X-Ray 6D Image Guidance (ExacTrac) in the Delivery of Stereotactic Body Radiotherapy (SBRT)*. Poster Presentation at the 54th American Society for Radiation Oncology (ASTRO) 2012 Annual Meeting, Boston, Massachusetts, October 28 – 31, 2012. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society for Radiation Oncology 54th Annual Meeting, Vol. 84, Issue 3, Supplement, Page 3743, Abstract 3396, 1 November 2012.
64. F. Wang, S. Das, J. Park, R. Badkul, S. Hus, **P. Kumar**. *Validation and Reliability of Free Breathing Cone Beam Computed Tomography (FB-CBCT) Imaging Guidance in Stereotactic Ablative Radiotherapy (SABR) of Lung Tumors*. Poster Presentation at the 54th American Society for Radiation Oncology (ASTRO) 2012 Annual Meeting, Boston, Massachusetts, October 28 – 31, 2012. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society for Radiation Oncology 54th Annual Meeting, Vol. 84, Issue 3, Supplement, Page S831, Abstract 3628, 1 November 2012.
65. S. Das, F. Wang, J. Park, B. Kimler, R. Badkul, **P. Kumar**. *Probability of Radiation Pneumonitis and Fibrosis after Stereotactic Ablative Radiotherapy (SABR) for Lung Cancer using NTCP model*. Oral Presentation at the 54th American Society of Therapeutic Radiation Oncology (ASTRO) 2012 Annual Meeting, Boston, Massachusetts, October 28 – 31, 2012. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society for Radiation Oncology 54th Annual Meeting, Vol. 84, Issue 3, Supplement, Page S107, Abstract 264, 1 November 2012.
66. Park, J., Das, S., Kimler, B.F., Badkul R., Nolan, N., **Kumar, P.**, Cox, G., Wang F. *Low Dose Volumes as the Driving Force of Radiographic Change after Stereotactic Ablative Body Radiation Therapy to the Lung*. Poster presentation at: 2013 American College of Radiation Oncology Annual Meeting; 2013 Feb 14-16; San Antonio, TX. Proceedings of American College of Radiation Oncology 2013; Abst. 18.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

67. **P. Kumar**, P. Veldhuizen, M. Thompson, X. Shen, J. Pinski. *Preliminary Results of an On-Going Phase I/II Trial of Tri-Modality Therapy using Hormonal Therapy, Radiation Therapy (RT) and concurrent Docetaxel in Patients with High Risk Pathologic T2-3N0M0 Prostate Cancer*. Poster discussion presentation at the 55th Annual American Society of Therapeutic Radiation Oncology Meeting, Atlanta, GA, Sept 22-25, 2013. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society of Therapeutic Radiation Oncology 55th Annual Meeting, Vol. 87, Number 2S, Supplement, Page S389, Abstract 2484, September 2013.
68. **P. Kumar**, P. Veldhuizen, M. Thompson, X. Shen, J. Coster, J. Pinski. *Feasibility and Efficacy of Tri-Modality Therapy in Patients with High Risk Pathologic T2-3N0M0 Prostate Cancer: Preliminary Results of an On-Going Phase I-II Trial*. Poster Presentation at: American Radium Society's 96th Annual Meeting; 2014 Apr 26-29; St. Thomas, U.S.V.I. Oncology, Vol. 28, Supplement 1, Page 70-71, Abstract P088, April 2014.
69. R Badkul, D Pokhrel, H Jiang, F Wang, **P Kumar**. *Dosimetric Evaluation and Clinical Implementation of IPlan Monte Carlo Algorithm For Lung Stereotactic Ablative Radiotherapy (SABR)*. Poster Presentation at: 2013 American Association of Physics in Medicine Annual Meeting; 2013 Aug 4-8; Indianapolis, Indiana. Proceedings 2013 AAPM Annual Meeting Program, Medical Physics, Vol. 40, No. 6, June 2013, Page 300, Abstract SU-E-T-413.
70. Rajeev K. Badkul, MS, DABR, Chris McClinton, M.D., **Parvesh Kumar, M.D.**, Melissa Mitchell, M.D., Ph.D. *Dose Volume Histograms (DVH) Analysis and Comparison with ICRU Point Doses in MRI Guided HDR Brachytherapy for Cervical Cancer*. Poster Presentation at: 2014 American Association of Physics in Medicine Annual Meeting; July 20-24, 2014; Austin, Texas. Medical Physics, Vol. 41, Issue 6, June 2014, page 348, Abstract SU-E-T-525.
71. R Badkul, D Pokhrel, H Jiang, J Park, F Wang and **P Kumar**. *Assessing the Validity of 4D-CT Based Target Volumes and Free Breathing CBCT Localization in Lung Stereotactic Ablative Radiation Therapy (SABR)*. Poster Presentation at: 2014 American Association of Physics in Medicine Annual Meeting; July 20-24, 2014; Austin, Texas. Medical Physics, Vol. 41, Issue 6, June 2014, Page 204, Abstract SU-E-J-207.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

72. D Pokhrel, R Badkul, H Jiang, C Estes, **P Kumar** and F Wang. *A Simple Correction-Based Method for Independent Monitor Unit (MU) Verification in Monte Carlo (MC) Lung SBRT Plans*. Poster Presentation at: 2014 American Association of Physics in Medicine Annual Meeting; July 20-24, 2014; Austin, Texas. Medical Physics, Vol. 41, Issue 6, June 2014, Page 227, Abstract SU-E-T-24
73. D Pokhrel, R Badkul, H Jiang, C Estes, J Park, **P Kumar** and F Wang. *BED Vs. Local Control: Radiobiological Effect of Tumor Volume in Monte Carlo (MC) Lung SBRT Planning*. Poster Presentation at: 2014 American Association of Physics in Medicine Annual Meeting; July 20-24, 2014; Austin, Texas. Medical Physics, Vol. 41, Issue 6, June 2014, Page 94, Abstract SU-C-BRE-02.
74. D Pokhrel, R Badkul, H Jiang, H Saleh, C Estes, J Park, **P Kumar** and F Wang. *Dosimetric Evaluation of Centrally Located Lung Tumors: A Monte Carlo (MC) Study of Lung SBRT Planning*. Poster Presentation at: 2014 American Association of Physics in Medicine Annual Meeting; July 20-24, 2014; Austin, Texas. Medical Physics, Vol. 41, Issue 6, June 2014, Page 167, Abstract SU-E-J-55.
75. F Wang, A Roy, R Badkul, J Park, **P Kumar** and H Staecker. *The Impact of Hypofractionated Linac-Based Stereotactic Radiotherapy upon Early Auditory Functions in the Treatment of Vestibular Schwannomas*. Poster Presentation at: 2014 Society for Neuro Oncology; November 13-16, 2014; Miami, Florida. Neuro-Oncology, Vol. 16: 122-133, 2014, Abstract MS-27.
76. C Estes, D Pokhrel, BF Kimler, R. Badkul, H Jiang, **P Kumar**, F Wang. *Comparative Analysis of Monte Carlo and Pencil Beam Algorithm-Derived Dose Distributions for Tumors and Normal Tissue in Lung Stereotactic Ablative Radiotherapy*. Poster Presentation at: 2014 American Society of Therapeutic Radiation Oncology, San Francisco, California, September 14-17, 2014. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society of Therapeutic Radiation Oncology 56th Annual Meeting, Vol. 90, Number 1S, Supplement, Page S905, Abstract 3763, September 1, 2014.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

77. **P Kumar**, PV Veldhuizen, M Thompson, X Shen, J Coster, J Pinski. *Recently Updated Preliminary Results of an On-Going Phase I/II Trial Using Tri-modality Therapy in Patients with Post-Prostatectomy High Risk Pathologic (p) T2-3N0M0 Prostate Cancer*. Poster Presentation at: 2014 American Society of Therapeutic Radiation Oncology, San Francisco, California, September 14-17, 2014. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society of Therapeutic Radiation Oncology 56th Annual Meeting, Vol. 90, Number 1S, Supplement, Page S457, Abstract 2622, September 1, 2014.
78. J Park, R Badkul, H Staecker, C Vijapura, **P Kumar**, F Wang. *Clinical Analysis of Patient Setup on Image-Guided Frameless Stereotactic Radiosurgery for Acoustic Neuromas*. Poster Presentation at: 2014 American Society of Therapeutic Radiation Oncology, San Francisco, California, September 14-17, 2014. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society of Therapeutic Radiation Oncology 56th Annual Meeting, Vol. 90, Number 1S, Supplement, Page S830 Abstract 3579, September 1, 2014.
79. D Pokhrel, R Badkul, H Jiang, C Estes, J Park, F Wang, **P Kumar**. *Clinical Evaluation of RTOG 0813 Dosimetric Criteria for Lung SABR Using iPlan Monte Carlo Algorithm*. Poster Presentation at: 2014 American Society of Therapeutic Radiation Oncology, San Francisco, California, September 14-17, 2014. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society of Therapeutic Radiation Oncology 56th Annual Meeting, Vol. 90, Number 1S, Supplement, Page S627, Abstract 3056, September 1, 2014.
80. X Shen, **P Kumar**. *The Long Term Twenty-Year Impact of PSA Screening in the US: Decrease in the Diagnosis of Stage IV Prostate Cancer (PC) Compared to Additional Treatment of Low/Intermediate Risk Disease PC*. Poster Presentation at: 2014 American Society of Therapeutic Radiation Oncology, San Francisco, California, September 14-17, 2014. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society of Therapeutic Radiation Oncology 56th Annual Meeting, Vol. 90, Number 1S, Supp., Page S154, Abstract 341, September 1, 2014.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

81. Fen Wang, John Park, Bruce F. Kimler, Rajeev K. Badkul and **Parvesh Kumar**. *Radiographic Changes in Lung of Patients Treated with Stereotactic Ablative Body Radiation Therapy and the Dosimetric Correlations*. Poster Presentation. 16th World Conference on Lung Cancer, September 6-9, 2015. Denver, CO. Journal of Thoracic Oncology, Vol. 10, Number 9, Supplement 2, September 2015, p. S441, Abstract P1.02-035.
82. Yongsook Lee, **Parvesh Kumar** and Melissa Mitchell. *An alternative option for reducing lung dose for electron scar boost irradiation in postmastectomy breast cancer patients with a thin chest wall*. Poster Presentation at: 2015 American Association of Physicists in Medicine Annual Meeting; July 12-16; 2015; Anaheim, CA. Medical Physics, Vol. 42, Number 6, June 2015, p. 3353, Abstract SU-E-T-95.
83. Rajeev Badkul, Sultan Nejaiman, Damodar Pokhrel, Hongyu Jiang, and **Parvesh Kumar**. *Comparative Analysis of Surface Dose Measurements Using MOSFET Detector and Dose Predicted by Eclipse - AAA with Varying Dose Calculation Grid Size*. Poster Presentation at: American Association of Physicists in Medicine Annual Meeting; July 12-16; 2015; Anaheim, CA. Medical Physics, Vol. 42, Number 6, June 2015, p. 3377, Abstract SU-E-T-196.
84. D Pokhrel, S Sood, R Badkul, H Jiang, **P Kumar**, F Wang. *Dosimetric Evaluation of Rib Dose in Peripheral Lung Tumors Treated with X-Ray Voxel Monte Carlo (XVMC) Based Lung Stereotactic Body Radiotherapy (SBRT) Following RTOG 0915 Guidelines*. Poster Presentation at: 2015 American Association of Physicists in Medicine Annual Meeting; July 12-16; 2015; Anaheim, CA. Medical Physics, Vol. 42, Number 6, June 2015, p. 3407, Abstract SU-E-T-322.
85. P. **Kumar**, P. V. Veldhuizen, M. Thompson, X. **Shen**, J. Coster, J. Pinski. *Preliminary Results of a Nearly Completed Phase I-II Trial Using Trimodality Therapy in Patients With Post Prostatectomy High Risk Pathologic (p) T2-3N0M0 Prostate Cancer*. Poster Presentation at: 57th Annual American Society of Therapeutic Radiation Oncology Meeting, San Antonio, TX, Oct. 18-21, 2015. International Journal of Radiation Oncology, Biology, Proceedings of the American Society of Therapeutic Radiation Oncology 57th Annual Meeting, Vol. 93, Issue 3, Supplement, Page E250, Abstract 2622, November 2015.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

86. R. Badkul, C. Lominska, D. Pokhrel, H. Jiang, F. Wang, **P. Kumar**. *Evaluating the Influence of Calculation Grid Size and Angular Resolution on Dosimetry of Head and Neck Plans Using Volumetric Modulated Arc Therapy (VMAT) Technique*. Poster Presentation at: 57th Annual American Society of Therapeutic Radiation Oncology Meeting, San Antonio, TX, Oct. 18-21, 2015. International Journal of Radiation Oncology, Biology, Proceedings of the American Society of Therapeutic Radiation Oncology 57th Annual Meeting, Vol. 93, Issue 3, Supplement, Page E624, Abstract 3563, November 2015.
87. F. Wang, A. Roy, R. Badkul, **P. Kumar**, H. Staecker. *The Impact of Hypofractionated Linac Based Stereotactic Radiation Therapy Upon Early Auditory Functions in the Treatment of Vestibular Schwannomas*. Poster Presentation at: 57th Annual American Society of Therapeutic Radiation Oncology Meeting, San Antonio, TX, Oct. 18-21, 2015. International Journal of Radiation Oncology, Biology, Proceedings of the American Society of Therapeutic Radiation Oncology 57th Annual Meeting, Vol. 93, Issue 3, Supplement, Page E111, Abstract 2282, November 2015.
88. Y. Lee, M. Mitchell and **P. Kumar**. *An alternative option for reducing lung dose for electron scar boost irradiation in postmastectomy breast cancer patients with a thin chest wall*. Poster Presentation at: 57th Annual American Society of Therapeutic Radiation Oncology Meeting, San Antonio, TX, Oct. 18-21, 2015. International Journal of Radiation Oncology, Biology, Proceedings of the American Society of Therapeutic Radiation Oncology 57th Annual Meeting, Vol. 93, Issue 3, Supplement, Page E618, Abstract 3550, November 2015.
89. Damodar Pokhrel, Sumit Sood, **Parvesh Kumar**, Christopher Lominska, Rajeev Badkul, Hongyu Jiang, and Fen Wang. *Volumetric Modulated Arc Therapy (VMAT) Significantly Reduces Treatment Time and Monitor Units for Whole-Brain Radiation Therapy (WBRT) While Still Meeting RTOG Protocol 0933 Hippocampal Sparing Constraints*. Poster Presentation at: 57th Annual American Society of Therapeutic Radiation Oncology Meeting, San Antonio, TX, Oct. 18-21, 2015. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society of Therapeutic Radiation Oncology 57th Annual Meeting, Vol. 93, Issue 3, Supplement, Page E621, Abstract 3556, November 2015.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

90. Damodar Pokhrel, Rajeev Badkul, Hongyu Jiang, **Parvesh Kumar**, and Fen Wang. *Dosimetric Comparison of Monte Carlo (MC) Versus Non MC RTOG 0915 Algorithms for the Calculation of Stereotactic Body Radiation Therapy (SBRT) Doses in the Treatment of Peripheral Non-Small Cell Lung Cancer (NSCLC) Lesions*. Poster Presentation at: 57th Annual American Society of Therapeutic Radiation Oncology Meeting, San Antonio, TX, Oct. 18-21, 2015. Int. J. of Radiation Onc., Biology and Physics, Proceedings of the ASTRO 57th Annual Meeting, Vol. 93, Issue 3, Supplement, Page S159, Abstract 1007, November 2015.
91. Christopher McClinton, Maryam Niroumand, Veer Shah, Jacqueline Hill, Reginald Dusing, **Parvesh Kumar**, and Xinglei Shen. *Patterns of Lymph Node Positivity on ¹¹C-acetate PET Imaging in Correlation to the RTOG Pelvic Radiation Field for Prostate Cancer*. Oral Presentation at: 57th Annual American Society of Therapeutic Radiation Oncology Meeting, San Antonio, TX, Oct. 18-21, 2015. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society of Therapeutic Radiation Oncology 57th Annual Meeting, Vol. 93, Issue 3, Supplement, Page S47, Abstract 103, November 2015.
92. **P. Kumar**, P. Veldhuizen, M. Thompson, X. Shen, and J. Pinski. *Trimodality Therapy Is Tolerable and Feasible in Patients With Postprostatectomy High-Risk Pathologic (p) T2-3N0M0 Prostate Cancer: Results of a Phase I-II Trial*. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the American Society for Therapeutic Radiation Oncology 58th Annual Meeting, Vol. 96, No. 25, Page S186, Abstract 1052, October 1, 2016 (Supplement).
93. **P. Kumar**, C. Cross, S. Moonie, J. and De Leon. *Rural-Urban Continuum as a Potential Geographic Correlate of Breast and Prostate Cancer Mortality in Nevada*. Poster Presentation at: 100th Annual American Radium Society Meeting, Orlando, FL, May 5-8, 2018. International Journal of Radiation Oncology, Biology and Physics, Vol. 101, Issue 2, Supplement, Page E40 – E41, June 1, 2018
94. **P. Kumar**, C. Cross, J. De Leon, and S., Moonie. *Impact of Mammography Screening Rates on Breast Cancer Mortality in Nevada (NV), California (CA) and US: Implications for Health Care Policy*. Poster Presentation at: 60th Annual American Society of Therapeutic Radiation Oncology Meeting, San Antonio, TX, Oct. 21-24, 2018. Int. J. of Radiation Onc., Biology and Physics, Proceedings of the ASTRO 60th Annual Meeting, Vol. 102, Number 3s, Supplement, Abstract TU-7-2959, October 2018.

I. SCHOLARLY PUBLICATIONS (continued)

Published / Presented Abstracts (continued):

95. C., Cross, **P. Kumar**, K. Callahan, S. Moonie, *Disparities in Colorectal Cancer Screening Prevalence and Mortality Rates in Nevada: A Population Health Analysis of Behavioral Risk*. Poster Presentation at: 2019 American Radium Society Annual Meeting, Dana Point, CA, Apr. 6-9, 2019. Int. J. of Radiation Oncology, Biology, Physics, Vol. 103, Number 5s, Supplement, page E53, April 2019.
96. **P. Kumar**, C. Cross, S. Moonie, *Breast and Prostate Cancer Screening Disparities and Mortality Rates in Nevada as Compared to California and the United States*. Poster Presentation at 2019 American Radium Society Annual Meeting, Dana Point, CA, Apr. 6-9, 2019. Int. J. of Radiation Oncology, Biology, Physics, Vol. 103, Number 5s, Supplement, pages E52-E53, April 2019.
97. Juli Petereit, Ruben Dagda, Yiliang Zhu, Josh Baker, **Kumar, P.** *Mountain West CTR-IN and NV INBRE Bioinformatics Collaborations to Foster Clinical Translational Research*. Poster Presentation at the 2019 NIH IDeA Western Regional Conference in Las Vegas, NV, October 7-9, 2019.
98. Chad L. Cross, Yiliang Zhu, **Kumar, P.** *Implementation of a Geographically Distributed Biostatistics, Epidemiology, and Research Design Core to Support Clinical and Translational Research in the Mountain West CTR-IN*. Poster Presentation at the 2019 NIH IDeA Western Regional Conference in Las Vegas, NV, October 7-9, 2019.
99. **Kumar, P.** *The Mountain West CTR-IN Program*. Poster Presentation at the 2019 NIH IDeA Western Regional Conference in Las Vegas, NV, October 7-9, 2019.
100. C Cross, PhD; **P Kumar, MD**, Las Vegas, NV; K Gutierrez, BS; S Moonie, *The Impact of Sociodemographic Factors in Breast, Prostate and Lung Cancer in the Patterns of Care Related to the Availability of Radiation Therapy (RT) in a Rural Mountain West State*. Poster Presentation at the 2019 Radiological Society of North America (RSNA) Conference in Chicago, IL, December 1, 2019.

I. SCHOLARLY PUBLICATIONS (continued)

Manuscript Publications:

1. Fontanesi J, Clark WC, Weir III A, Barry AD, **Kumar P**, Miller A, Eddy T, Tai D, Kun LE. *Interstitial Iodine-125 and Concurrent Cisplatin Followed by Hyperfractionated External Beam Irradiation for Malignant Supratentorial Glioma: Preliminary Experience at the University of Tennessee, Memphis.* Am J Clin Oncol 16:412-417, 1993.
2. **Kumar P**, Mulhern RK, Regine WF, Rivera GK, Kun LE. *A Prospective Neurocognitive Evaluation of Children Treated with Additional Chemotherapy and Craniospinal Irradiation Following Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia.* International Journal of Radiation Oncology Biology Physics 31(3):561-566, 1995.
3. Regine WF, Fontanesi J, **Kumar P**, Ayers D, Bowman LC, Pappo AS, Coffey DH, Avery L, Rao BN, Kun LE. *Local Tumor Control in Rhabdomyosarcoma Following Low-Dose Irradiation: Comparison of Group II and Select Group III Patients.* International Journal of Radiation Oncology Biology Physics 31(3):485-491, 1995.
4. **Kumar P**, Kun LE, Hustu HO, Mulhern RK, Coffey DH, Hancock ML, Rivera GK. *Survival Outcome Following Isolated Central Nervous System Relapse Treated with Additional Chemotherapy and Craniospinal Irradiation in Childhood Acute Lymphoblastic Leukemia.* International Journal of Radiation Oncology Biology Physics 31(3):477-483, 1995.
5. Regine WF, Fontanesi J, **Kumar P**, Zeitzer K, Greenwald C, Bowman L, Shapiro DN, Rao BN, Kun LE. *A Phase II Trial Evaluating Selective Use of Altered Radiation Dose and Fractionation in Patients with Unresectable Rhabdomyosarcoma.* International Journal of Radiation Oncology Biology Physics 31(4):799-805, 1995.
6. Sugarbaker D, Herndon J, Kohman L, Krasna M, Green M, and the CALGB Thoracic Surgery Group (Altorki N, Dresler C, DeCamp MM, Ferguson M, Jaklitsch MT, Kass F, **Kumar P**, Maddaus MM, Nugent WC, Olak J, Reed C, Shennib H). *Results of CALGB 8935: A Multi-Institutional Phase II Tri-Modality Trial for Stage IIIA (N₂) Non-Small Cell Lung Cancer.* J Thorac Cardiovasc Surg 109:473-485, 1995.
7. **Kumar P**, Herndon J, Langer M, Kohman L, Shennib H, Elias A, Kass F, Eaton W, Seagren S, Green M, Sugarbaker D. *Patterns of Disease Failure After Tri-Modality Therapy of Non-Small Cell Lung Cancer (NSCLC) Pathologic Stage IIIA (N₂): Analysis of Cancer and Leukemia Group B (CALGB) Protocol 8935.* Cancer 77(11):2393-2399, 1996.

I. SCHOLARLY PUBLICATIONS (continued)

Manuscript Publications (continued):

8. Robbins KT, Fontanesi J, Wong FSH, Vicario D, Seagren S, **Kumar P**, Weisman R, Pelliteri P, Thomas R, Gold R, Palmer R, Weir A, Kerber C, Murry T, Ferguson R, Los G, Howell SB. *A Novel Organ Preservation Protocol for Advanced Carcinoma of the Larynx and Pharynx.* Archives of Otolaryngology--Head and Neck Surgery 122(8):853-857, 1996.
9. Robbins KT and **Kumar P**. *Proliferation of Epithelia of Non-Involved Mucosa in Patients with Head and Neck Cancer.* The Otolaryngology Journal Club Journal 4(3):123-125, June 1997.
10. Robbins KT, **Kumar P**, Regine WF, Wong FS, Weir III A, Flick PA, Palmer R, Murry T, Fontanesi J, Ferguson R, Thomas R, Hartsell W, Paig CU, Salazar G, Norfleet L, Hanchett C, Harrington V, Niell HB. *Efficacy of Targeted Supradose Cisplatin and Concurrent Radiation Therapy for Advanced Head and Neck Cancer: The Memphis Experience.* Int J Radiat Oncol Biol Phys 38(2):263-271, 1997.
11. Aggarwal R, Yeung D, **Kumar P**, Muhlbauer M, Kun LE. *Efficacy and Feasibility of Stereotactic Radiosurgery in the Primary Management of Unfavorable Pediatric Ependymoma: A Phase II Pilot Study.* Radiotherapy and Oncology 43(3):269-273, 1997.
12. **Kumar P**. *The Role of Thoracic Radiation Therapy in the Management of Limited Stage Small Cell Lung Cancer.* Chest 112(4):259S-265S, 1997.
13. **Kumar P**. *The Role of Thoracic Radiation Therapy in the Combined Modality Treatment of Non-Small Cell Lung Cancer.* Veterans Health System Journal 2(6S):19-21, 1997.
14. Dennys D, **Kumar P**, Wong FSH, Newman LA, Robbins KT. *The Predictive Value of Tumor Regression Rates During Chemoradiation Therapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.* The American Journal of Surgery 174:561-564, 1997.
15. Newman LA, Vieira F, Schwiezer V, Samant S, Murry T, Woodson G, **Kumar P**, Robbins KT. *Eating and Weight Maintenance Following Chemoradiation for Advanced Head and Neck Cancer.* Archives of Otolaryngology - Head and Neck Surgery 124(5):589-592, 1998.

I. SCHOLARLY PUBLICATIONS (continued)

Manuscript Publications (continued):

16. **Kumar P.** *Is Radiation Therapy The Standard of Care for Advanced Oropharyngeal Carcinoma?* Disease Management and Clinical Outcomes, 1(6):190-194, 1998.
17. Niell HB, **Kumar P**, Miller AA, Griffin JP. *A Phase I/II Dose Escalation Trial Evaluating the Toxicity and Efficacy of Induction Cisplatin and Paclitaxel Followed by Combined Chemoradiation Therapy in Stage III Non-Small Cell Lung Cancer.* Cancer Therapeutics 2:67-74, 1999.
18. Samant S, **Kumar P**, Wan J, Hanchett C, Vieira F, Murray T, Wong FSH, Robbins KT. *Concomitant Radiation Therapy and Supradose Intra-Arterial Targeted Cisplatin Chemotherapy for the Treatment of Advanced Pyriform Sinus Squamous Cell Carcinoma: Disease Control and Preservation of Organ Function.* Head and Neck 10:21(7):595-601, 1999.
19. Robbins KT, Wong FSH, **Kumar P**, Hartsell W, Vieira F, Mullins B, Niell HB. *Efficacy of Targeted Chemoradiation and Planned Selective Neck Dissection (SND) to Control Bulky Nodal Disease in Advanced Head and Neck Cancer.* Archives of Otolaryngology - Head and Neck Surgery, 6:125(6):670-5, 1999.
20. **Kumar P.** *Impact of Anemia and Tumor Hypoxia in Patients with Head and Neck Cancer.* The Oncologist, 5(2):13-18, June 2000.
21. Robbins KT, **Kumar P**, Wong, FSH, Hartsell W, Flick P, Palmer R, Weir AB, Neill HB, Murry T, Ferguson R, Hanchett C, Vieira F, Bush A, Howell S. *Targeted Chemoradiation for Advanced Head and Neck Cancer: Analysis of 213 Patients.* Head & Neck, 22(7):687-93, Oct 2000.
22. **Kumar P.** *Tumor Hypoxia and Anemia: Impact On the Efficacy of Radiation Therapy.* Seminars in Hematology, 37(4 Suppl 6):4 – 8, Oct. 2000.
23. **Kumar P.** *Importance of Anemia As A Prognostic Factor In Patients With Head and Neck Cancer.* Anemia in Oncology, 3(6):2-4, Dec. 2000.
24. **Kumar P**, Robbins KT. *Treatment of Advanced Head and Neck Cancer with Intra-Arterial Cisplatin and Concurrent Radiation Therapy: The “RADPLAT” Protocol.* Current Oncology Reports, 3(1):59-65, Jan. 2001.

I. SCHOLARLY PUBLICATIONS (continued)

Manuscript Publications (continued):

25. DiPaola R, **Kumar P**, Hait W, Weiss R. *State-of-the-Art Prostate Cancer Treatment and Research. A Report from The Cancer Institute of New Jersey.* New Jersey Medicine, February 2001, 23-33.
26. Samant S, Robbins KT, **Kumar P**, Vieira F, Hanchett C. *Bone or Cartilage Invasion by Advanced Head and Neck Cancer: Intra-Arterial Supradose Cisplatin Chemotherapy and Concomitant Radiotherapy for Organ Preservation.* Arch Otolaryngol Head Neck Surg.,127(12):1451-6, 2001.
27. **Kumar P.** *RADPLAT: A Novel Approach to Treating Advanced Head and Neck Cancer.* Federal Practitioner 19(4):18-21, April 2002.
28. **Kumar P.** *Chicken or egg: how does anemia influence prognosis of cancer patients?* Focus on Anemia in Cancer, 3(1):24-26, 2002.
29. **Kumar P**, Meluch T, Chougule P. *Timing of Chemotherapy with Local Treatment in Advanced Head and Neck Cancer.* Federal Practitioner 19(4):14-17, April 2002.
30. **Kumar P.** *New Paradigms in Localized Prostate Cancer: The Role of Chemotherapy Combined with 3-D Conformal Radiation Therapy.* Advances in Prostate Cancer, 6(3):3-5, 2002.
31. Chougule P, Meluch T, **Kumar P.** *Early Detection of Head and Neck Cancer.* Federal Practitioner 19(4):5-6, April 2002.
32. **Kumar P**, Chougule P, Meluch T. *Managing Anemia in Patients Undergoing Treatment for Head and Neck Cancer.* Federal Practitioner 19(4):22-23, April 2002.
33. Chougule P, **Kumar P**, Meluch T, Douda D. *Question and Answer Session: Challenges in Treating Head and Neck Cancer; Cisplatin Versus Carboplatin; Managing the Adverse Effects of Therapy.* Federal Practitioner 19(4):24-25, April 2002.
34. Elias AD, **Kumar P**, Herndon J, Skarin AT, Sugarbaker DJ, Green M. *Radiotherapy Versus Chemotherapy Plus Radiotherapy in Surgically Treated IIIA N₂ Non-Small Cell Lung Cancer.* Clinical Lung Cancer, 4(2):95-103, September 2002.
35. **Kumar P.** *A New Paradigm for the Treatment of High-Risk Prostate Cancer: Radiosensitization with Docetaxel.* Reviews in Urology 5 (Supplement 3): S71 – S77, 2003.

I. SCHOLARLY PUBLICATIONS (continued)

Manuscript Publications (continued):

36. Robbins KT, Samant S, Vieirra F, **Kumar P**. *Pre-Surgical Cyto-reduction of Oral Cancer Using Intra-Arterial Cisplatin and Limited Concomitant Radiation Therapy*. Archives of Otolaryngology and Head and Neck Surgery 130(1):28-32, January 2004.
37. Robbins KT, Doweck I, Samant S, Vieirra F, **Kumar P**. *Factors Predictive of Local Disease Control Following Intra-Arterial Concomitant Chemoradiation (RADPLAT)*. Laryngoscope 114(3):411-7, March 2004.
38. **Kumar P**, Perrotti M, Weiss R, Todd M, Goodin S, Cummings K, DiPaola R. *Phase I Trial Evaluating the Maximally Tolerated Dose of Weekly Docetaxel With Concurrent 3-D Conformal Radiation Therapy in the Treatment of Localized Unfavorable Adenocarcinoma of the Prostate*. Journal of Clinical Oncology 22:1909-1915, 2004.
39. Robbins KT, **Kumar P**, Harris J, McCulloch T, Cmelak A, Sofferman R, Levine P, Weisman R, Wilson W, Weymuller E, Fu K. *Supradose Intra-Arterial Cisplatin and Concurrent Radiation Therapy for the Treatment of Stage IV-T4 Head and Neck Squamous Cell Carcinoma Is Feasible and Efficacious In a Multi-Institutional Setting: Results of Radiation Therapy Oncology Group Trial 9615*. Journal of Clinical Oncology 23(7):1447-1454, 2005.
40. Jaklitsch MT, Herndon II J., DeCamp MM, Richards WG, **Kumar P**, Green MR, Sugarbaker DJ. *Nodal Down staging Predicts Survival Following Induction Therapy For Stage IIIA (N₂) Non-Small Cell Lung Cancer in CALGB 8935*. Journal of Surgical Oncology 94:599-606, 2006.
41. Perrotti M, Doyle T, **Kumar P**, McLeod D, Badger W, Prater S, Moran M, Rosenberg S, Bonatsos C, Kreitner C, Kiehl R, Chang T, Kolodziej M. *Phase I/II Trial of Docetaxel and Concurrent Radiation Therapy in Localized High Risk Prostate Cancer (AGUSG 03-10)*. Urol Oncol, 26(3):276-80, May-June 2008.
42. Kang JJ, Eaton M, Streeter O, **Kumar P.**, *Mucosa-Associated Lymphoid Tissue Lymphoma and Concurrent Adenocarcinoma of the Prostate: A Rare Case Report and Review of the Literature*. Rare Tumors, Vol. 2, No.3 154-157, 2010

I. SCHOLARLY PUBLICATIONS (continued)

Manuscript Publications (continued):

43. Wang, F., **Kumar, P.**, *The Role of Radiotherapy in Management of Pancreatic Cancer.* J. Gastrointest Oncol, Vol. 2, No. 3 157-167, 2011.
44. Damodar Pokhrel, Rajeev Badkul, Hongyu Jiang, **Parvesh Kumar**, Fen Wang. *Technical Note: Dosimetric Evaluation of Monte Carlo Algorithm in iPlan for Stereotactic Ablative Body Radiotherapy (SABR) for Lung Cancer Patients Using RTOG 0813 Parameters.* Journal of Applied Clinical Medical Physics, Vol. 16, No. 1, pp. 5058 - 5068, January 8, 2015.
45. Pokhrel D, Sood, S, Badkul R, Jiang H, Lominska C, **Kumar P**, Wang F. *Assessment of Monte Carlo Algorithm for Compliance with RTOG 0915 Dosimetric Criteria in Peripheral Lung Cancer Patients Treated with Stereotactic Body Radiotherapy.* Journal of Applied Clinical Medical Physics, Vol. 16, No. 5, pp. 131 – 141, April 28, 2015.
46. Damodar Pokhrel, Sumit Sood, Christopher Lominska, **Parvesh Kumar**, Rajeev Badkul, Hongyu Jiang, Fen Wang. *Potential for Reduced Radiation-Induced Toxicity Using Intensity-Modulated Arc Therapy for Whole Brain Radiotherapy with Hippocampal Sparing.* Journal of Applied Clinical Medical Physics, Vol. 16, No. 5, pp. 5587 - 5597, September 8, 2015.
47. John Park, Saikat Das, Bruce F. Kimler, Rajeev Badkul, Nicole Nolan, **Parvesh Kumar**, Glendon Cox, Fen Wang. *Radiographic Changes in Lung of Patients Treated with Stereotactic Ablative Body Radiation Therapy: Low-Dose Volumes as the Driving Force for Radiographic Change.* Journal of Radiation Oncology, Volume 5, pp. 265-272, 2016.
48. Xinglei Shen, **Parvesh Kumar**. *Trade-Off Between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.* Journal of Urology, Vol. 195, No. 5, pp. 1397 – 1402, May 2016.
49. Y. Lee, **Parvesh Kumar**. *An Alternative Option to Reduce Lung Dose for Electron Scar Boost Irradiation in Post-Mastectomy Breast Cancer Patients with a Thin Chest Wall.* Journal of Radiotherapy in Practice, Volume 16, Issue 1, pp. 20 – 28, March 2017.
50. Jeffrey Cummings, Carl Reiber, **Parvesh Kumar**. *The Price of Progress: Funding and Financing Alzheimer's Disease Drug Development.* Alzheimer's & Dementia: Translational Research & Clinical Interventions, Volume 4, pp. 330-343, June 2018.